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ABSTRACT 
This report was prepared for the molecular diagnostic laboratory at Children’s and 
Women’s Hospital in Vancouver B.C. and makes a business case for the introduction of a 
new genetic diagnostic test designed to detect patients that are susceptible to adverse 
reactions to the drug carbamazepine. This is a relatively small market requiring a 
maximum of 2,600 tests a year which could easily be integrated into the laboratory’s 
current operations. It is proposed that provision of the service be free to the patients of 
British Columbia at maximum added cost of $20,000 per year, which could be more than 
recovered by offering the test to the rest of Canada at a recommended $99 per test.  At 
this time, this program is an ideal starting point for the laboratory to expand the scope of 
its services into safety pharmacogenetics and establish itself as a leader in this emerging 
field. 
Keywords: Business Case, molecular diagnostics industry, market analysis 
pharmacogenomics 
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EXECUTIVE SUMMARY 
The emerging field of pharmacogenomics, which allows healthcare providers to 
tailor medication to an individual’s genetic profile in order to improve safety and 
efficacy, is now ready for the clinic; however, the healthcare system has not kept up.  
While there are at least 27 drugs on the market with recommendations for pre-therapy 
pharmacogenetic testing, less than a handful are routinely applied in the clinic.  This 
oversight exposes patients to suboptimal therapy and/or unacceptable risk and exposes 
the system to unnecessary costs associated with hospitalization when therapies fail or 
result in severe adverse reactions.  The molecular diagnostic laboratory at Children’s and 
Women’s hospital proposes to address this situation by initiating a pharmacogenomics 
program for British Columbia with the introduction of testing for hypersensitivity to the 
drug carbamazepine.  
Because of its simplicity and potential to save lives, carbamazepine sensitivity 
testing is an ideal candidate for initiating these services.  While effective for epilepsy, 
bipolar disorder and neuropathic pain, carbamazepine is known to cause rare but deadly 
skin reactions called Steven’s Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis 
(TEN).  Fortunately, recent research has uncovered a genetic marker that will predict the 
risk of these reactions in patients of Han Chinese descent – a population where it has 
been reported that 1 in 400 patients suffer from carbamazepine induced SJS/TEN.  Both 
Health Canada and the Food and Drug Administration in the United States recommend 
pre-therapy genetic testing for hypersensitivity in this population. The costs of initiating 
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such a program in British Columbia is examined here as well as the potential for 
providing this service to the rest of the Canada for a fee. 
According to estimates, approximately 900 patients of Han-Chinese descent are at 
risk of carbamazepine – induced SJS each year in British Columbia and therefore eligible 
for testing.  It is anticipated that the laboratory has the capacity to take on this work with 
its current resources and therefore the only new money required will be to cover the 
variable costs associated with testing.  This is estimated to be a maximum of 
approximately $20,000 if all eligible patients access the program and about half that 
based on projected uptake by the medical community.  As the average costs of treating a 
case of SJS/TEN is approximately $20,000, averting just one of these reactions per year 
will pay for the program. 
Establishing a carbamazepine sensitivity program in BC presents an opportunity 
for the laboratory to become the reference laboratory for this test in the rest of Canada 
where it is estimated that 1,700 Han-Chinese patients per year are exposed to this risk. 
Most provinces do not have the patient population to warrant their own programs and 
therefore physicians in those jurisdictions will be looking externally for this service. With 
strategic pricing (ca. $99 per test) and marketing plan, it is anticipate that the laboratory 
could garner all this work and realize an annual gross profit of $25,000 per year based on 
projected uptake and up to $95,000 with full uptake (i.e. 1,700 test per year). 
It is the conclusion of this report that initiation of this program is a relatively low 
risk venture with a very positive upside.  Not only does it offer the best care for the 
patients of British Columbia but it has the potential to save the system money and 
generate a source of funds to support laboratory overhead costs.  Importantly, the 
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program is expected to generate other opportunities as the laboratory expands its horizons 
and becomes a transitional leader in bringing pharmacogenomic research to the clinic. 
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GLOSSARY 
 
Abacavir Anti viral drug indicated for HIV infection 
Adverse Drug Reaction 
(ADR) 
An unintended response to a medication that worsens a 
patient’s health or wellbeing. 
Azathioprine Immunosuppressant indicated for organ transplant and 
autoimmune diseases.  
Carbamazepine Anticonvulsant and mood stabilizer indicated for epilepsy, 
trigeminal neuralgia and bipolar disorder 
Genotyping Characterizing an organism according to its genetic code. 
Human Leukocyte 
Antigen (HLA) 
Describes the genes that encode the proteins presented on the 
surface of white blood cells which identify the cells as being 
endogenous to the organism.  
Incidence Epidemiological term used to describe the number of new 
cases of a disease or conditions diagnosed in a year. 
Irinotecan Anticancer drug indicated for metastatic carcinoma of the 
colon or rectum 
Lamotrigine Anticonvulsant and mood stabilizer indicated for the treatment 
of epilepsy and bipolar disorder. 
Neuropathic Pain Pain derived from injury to the nerves rather than injury to a 
body part 
Pharmacogenetics The study of genetic factors that affect the response to a drug. 
Generally used interchangeably with pharmacogenomics. 
Pharmacogenomics The clinical management of disease with the use of genetic 
information. Generally used interchangeably with 
pharmacogenetics. 
Phenytoin Anticonvulsant indicated for epilepsy 
 xii 
Phlebotomy The practice of drawing blood from a vein 
Polymorphism Describes any variation in the genetic code that is prevalent in 
greater than 1% of the population 
Rasbuicase Medication indicated for hyperuricemia (build up in the blood 
of uric acid) 
Valproic Acid Anticonvulsant drug indicated for Epilepsy 
Warfarin Anticoagulant drug indicated for treatment and prophylaxis of 
atrial fibrillation, thrombolytic embolism and stroke.  
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1:  ITRODUCTIO 
The purpose of this report is to develop a business case for the creation of a 
clinical pharmacogenomic testing program in the province of British Columbia for 
averting adverse drug reactions (ADRs).  Briefly, this is the practice of pre-testing 
patients for known genetic markers of ADRs allowing physicians to better assess the 
risks and benefits associated with certain drugs.  When provided with a result suggesting 
a patient might be susceptible to an ADR, doctors might choose to prescribe alternative 
medication or simply monitor the patient more closely.  This is in contrast to the current 
practice of prescribing a drug and counselling the patient to watch out for the early 
symptoms of ADRs and to discontinue therapy if they appear. 
This report was prepared on behalf of the Molecular Diagnostic Testing 
Laboratory at Children’s and Women’s Hospital in Vancouver British Columbia with the 
intention of presenting the case to the Provincial Health Service Authority (PHSA).  The 
PHSA is responsible for the funding and administration of all healthcare programs with a 
province-wide scope including all genetic testing services.  Currently the only such 
testing offered provincially is limited to genetic disease (e.g. cystic fibrosis, Huntington’s 
disease etc.) and a case is made here to extend the laboratory’s mandate to include 
pharmacogenetic safety testing. 
While there are a number of drugs on the market where pharmacogenomic testing 
is warranted, this report focuses on the development of a testing program for the drug 
carbamazepine, to serve as a demonstration project for a larger more extensive program.  
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The primary purpose of this program is to provide the patients of British Columbia with 
state-of-the-art health care service; however, the report also examines the potential of 
providing this test to physicians in the rest of Canada as a means of recovering some of 
the costs.  
Thus this document  develops the business case for HLA-B genotyping for 
carbamazepine sensitivity and is organized to facilitate a well developed understanding of 
the potential of this opportunity.  As such the report progressively provides the following: 
• An analysis of the clinical laboratory testing industry. 
• A description of the potential for pharmacogenomics in healthcare with a 
specific focus on the current opportunity (i.e. carbamazepine sensitivity 
testing). 
• A description of the resources and capabilities of the laboratory and team 
leaders to highlight the reasons why the molecular diagnostics laboratory 
and Children’s and Women’s Hospital is the ideal setting for this program.   
• An analysis of the market as it pertains to carbamazepine sensitivity 
testing. 
• An examination of the resources that will be required to provide this 
service for the patients of British Columbia. 
• An analysis of the potential for the laboratory to serve as a reference 
laboratory to the rest of Canada providing the test for a fee.  This analysis 
includes a recommended pricing strategy designed to minimize risk while 
encourage demand and discourage potential competition. 
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• A high level plan for the program role out and commercialization 
including a communication plan and financial requirements. 
• An examination of the risks and opportunities associated with the 
introduction of the program.  
It is believed that these analyses provide an accurate and comprehensive portrait 
of the opportunity.  In addition to a thorough review of the medical, scientific and biotech 
business literature, these analyses drew upon the databases of Brogan Inc, a research firm 
that compiles drug reimbursement data from selected private research firms across the 
country. Costs analysis included the opinions of molecular diagnostics laboratorians and 
representatives from a number of prominent suppliers within the industry (e.g. Applied 
Biosystems, Qiagen, Illumina, Luminex).  Furthermore, the opinions and experience of a 
number of relevant healthcare professionals have been integrated into the analysis 
including neurologists, psychiatrists, pharmacy doctorates working within the BC 
Healthcare/Research system, and a retired senior healthcare executive currently working 
within the healthcare evaluation and intelligence industry.  After completion of this 
analysis, it is the opinion of the author that genotype testing for carbamazepine sensitivity 
represents a good investment of healthcare dollars allowing the province to lead the way 
to a future of safer, more manageable healthcare for Canadians and British Columbians 
alike. 
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2:  THE IDUSTRY 
Clinical laboratory diagnostic testing is an essential component of healthcare 
delivery providing hundreds of conventional tests (American Association for Clinical 
Chemistry, 2008) that inform over 80% of medical decision making (Boone, 2004).  In 
British Columbia these service account for approximately 5% of all healthcare 
expenditures (British Columbia Provincial Laboratory Coordinating Office, 2005). While 
currently representing only a small percentage of the market, the relatively new field of 
molecular diagnostics is having a disruptive effect on the industry attracting hundreds of 
new players to the market.  Molecular diagnostic testing is a term that has been used to 
describe tests specifically characterizing the nucleic acid make up of DNA and/or RNA.  
Because these molecules encode the entire complexity of human form and function, we 
are only just beginning to scratch the surface of our understanding of their effect on 
human health – new knowledge is emerging daily.  At the same time, technological 
advances have made it practical to rapidly and economically apply this new knowledge to 
patient care once it becomes clinically indicated.  Under these circumstances, the market 
for these services has become highly fragmented with a minimum of 408 North American 
and 189 foreign clinical laboratories currently providing these services internationally, as 
listed on the National Institutes of Health’s GeneTest website (National Institutes of 
Health, 2008).  In fact, fragmentation is most probably greater than these numbers imply 
as this count likely represents only the most reputable laboratories in the world and is 
probably a considerable underestimate of the competition worldwide. 
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In 2005, molecular diagnostic testing represented approximately 3% of the $36.5 
billion in vitro diagnostic industry; however this sector is undergoing tremendous growth.  
Annual worldwide sales of these tests have grown from approximately 1.1 billion in 2005 
(Doig, 2007)  to an estimated 2.5 billion last year; although that growth has been driven 
primarily by infectious disease (Figure 1).  In these cases, genetic tests are characterizing 
the genetic profile of the invading pathogen and not the human host.  Such tests have 
proven to be very useful in diagnosing infection or predicting treatment response and in 
many cases have been rapidly embraced by the medical community.  In contrast, the 
more human application of molecular diagnostics is still early in the technological 
lifecycle and has tremendous potential for growth. In fact, the cancer, personalized 
medicine and traditional genetics sectors of in Figure 1are projected to experience annual 
growth rates of 20%, 20% and 15% respectively in a five year period (Sannes, 2008).  
With proper planning and execution, it should be possible to prosper from this growth. 
 
Figure 1: Breakdown of Laboratory services provided by the Molecular Diagnostic 
Market. Derived from data provided in (Sannes, 2008). 
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In spite of the seemingly competitive molecular diagnostic market, margins on 
many of these tests are relatively high making this an attractive business.  The reasons for 
this are two –fold.  First, many tests are relatively esoteric and for many laboratories, the 
low demand does not warrant the resources that would be required to supply the service.  
Therefore, only larger laboratories generally take on this work; but only at a premium.  In 
addition, current market prices often reflect older methodologies and have not kept pace 
with falling operating costs. There is little incentive to lower price in a supply challenged 
market.  These conditions have created an environment that is lucrative enough that the 
two biggest players, LabCorp and Quest diagnostics, are increasing their esoteric 
operations (Laboratory Corporation of America Holdings Inc, 2007; Quest Diagnostics, 
2007).  With in excess of 1500 tests from which to choose (National Institutes of Health, 
2008), this should still leave enough room in the market for smaller players to find a 
niche. 
Of course the molecular diagnostics industry is defined by more than just the 
laboratories providing these services. It encompasses the entire value chain from the 
multitude of suppliers to an even greater number of consumers within the healthcare 
community.  In addition there are a number of peripheral players that can influence the 
course of events. Figure 2, shows the familiar five forces originally outlined by Porter 
(Porter, 1980) plus two other important forces that diagnostic laboratories need to 
contend with; regulators and complements.  Each of these forces represents threats and/or 
opportunities to molecular diagnostic laboratories and it important to develop an 
understanding the pressures they exert.  
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Figure 2: Forces influencing the molecular diagnostics reference laboratory. Arrows 
represent the direction and relative magnitude of force exerted by each party on the 
other. 
Suppliers: While there are easily over 50 companies supplying machinery, reagents, 
consumables, and/or test kits for molecular diagnostic testing, the transaction costs 
associated with dealing with more than a few can be overwhelming.  These companies 
offer a myriad of technological platforms for the characterization of DNA; however, 
given the time and money involved in adopting these technologies, most laboratories 
restrict themselves to just a few.  Thus, the original choice(s) can lock a laboratory into a 
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proprietary technology for years potentially limiting its bargaining position with respect 
to ongoing purchases associated with that technology.  For smaller operations, 
negotiating favourable prices for consumables can be challenging.  Fortunately, this is 
becoming somewhat less of an issue as the degree of standardization and the availability 
of generic supplies has increased.  Nevertheless, most technologies require an ongoing 
relationship with the original vendor for at least some supplies and service contracts and 
these are usually priced at a premium.  There is a limitation to opportunism on the part of 
vendors, however, as the lifecycle of most technological platforms in this field have 
become so abbreviated that it is counterproductive to exploit their customers – they must 
provide value. Most major vendors recognize this and they differentiate themselves with 
quality, ease of use and superior customer service which in most cases are at least as 
important as ongoing costs of supplies. In this respect, power is shifting in favour of the 
clinical laboratory. 
Substitutes: Being relatively new, molecular diagnostic testing is considered by 
most to be the substitute for the current standard of care. Whether that involves an 
alternative test, clinical monitoring, or doing nothing at all, the major question from the 
perspective of the diagnostics laboratory is: does a new test offer value beyond the 
current clinical practice.  In the case of adverse drug reactions, the standard of care often 
involves simply counselling the patient to monitor themselves for early signs of adverse 
events and discontinuing the drug if they appear.  If caregivers feel that that is enough, 
new tests may be a difficult sell – if not, the tests are likely to be welcomed. In general, 
the relative strength of a substitute test in the market will be case dependant. 
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Complements:  Clinical application of molecular diagnostic testing is primarily 
for the prognosis and/or diagnosis of heritable disease and response to drugs. In the case 
of the latter, understanding drugs as a complement to testing is relatively straightforward 
– without the drug, the test would serve no purpose.  This might suggest that 
pharmaceutical companies would be natural allies of the pharmacogenetic testing 
laboratories; however, drugs with dangerous side-effects have been marketed for years 
without complementary safety tests and therefore the interest of pharmaceutical 
companies in this technology is less straightforward.  If a new drug is not being adopted 
by healthcare professionals or is at risk of being pulled from the market because of 
ADRs, pharmaceutical companies would be far more likely to support a test that could 
improve their competitive position.  On the other hand, they are far less likely to be 
interested in diagnostic tests for older, off-patent drugs that have become generic, 
especially if healthcare providers have become accustomed to managing the side effects.  
Thus, the relative influence of laboratories offering pharmacogenetic tests over the 
pharmaceutical companies supplying the complementary drugs will be case dependant.  
Customers:  Like most healthcare services, the customer configuration for 
diagnostic services in complex.  The patients are the main beneficiaries while physicians 
are the purchase decision makers and in Canada, provincial health ministries and 
agencies thereof make the decisions about payment on behalf of the taxpayer.  While all 
these stakeholders are important, the general power brokers are physicians. Individually 
they decide whether a diagnostic test is appropriate for use on a case-by-case base basis 
and collectively, they determine whether a test qualifies as the standard of care.  The 
latter is crucial for convincing health authorities (whether provincially, regionally or 
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locally) that diagnostic tests should receive public funding.  Generally speaking, it can be 
costly to convince the medical profession to adopt new technologies because it requires 
strong scientific and clinical evidence. 
Laboratories have little leverage in their relationship with physicians.  Like any 
other product, new diagnostic tests must win over physicians by proving their clinical 
worth and the onus is on the laboratories offering these tests to educate physicians about 
the test and make the test as compatible as possible with clinical practice. Even when a 
diagnostic test becomes mainstream, industry standards with respect to the cost, speed 
and quality of service give physicians the upper hand.  In spite of the relative newness of 
the technology and associated lack of standards, molecular diagnostic tests will not 
change this dynamic – at least in the long run.  Checks and balances (and 
communication) within the medical profession are pervasive, so that opportunistic 
laboratories will not survive for very long. In the final analysis, the balance of power is 
with the customer. 
Regulators:  All diagnostic service laboratories are subject to regulatory 
oversight to assure good laboratory practice (GLP). In British Columbia, oversight is 
provided by the Diagnostic Accreditation Program of the BC College of Physicians and 
Surgeons (DAP) while in the US it is the Clinical Laboratory Improvement Amendment 
(CLIA).  Without accreditation by these and other regional organizations, laboratories 
cannot provide diagnostic services in the associated jurisdictions.  While diagnostic 
laboratories have little leverage in these relationships, the regulators provide a stabilizing 
influence by clearly laying out the rules; however the situation is a little less clear with 
respect to molecular diagnostics. 
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Regulation of molecular diagnostic testing is in a state of flux.  Because of the 
complexity of the science, many of the rules associated with conventional diagnostic 
testing cannot be applied to molecular diagnostic testing.  As such, many regulatory 
agencies do not have fully developed codes for molecular diagnostic operations. This 
raises the risk of future unforeseen costs for molecular diagnostic laboratories as new 
regulatory requirements emerge. Once the regulations are developed, laboratories 
operating in this space will have no option but to comply.  In the developed world, 
regulations are supreme. 
Potential Entrants: University hospitals are often the birthplace of much of new 
knowledge associating genetic variations with clinical outcomes and the researchers 
involved are generally ahead of the curve with regard to techniques and understanding of 
the science.  Under these circumstances, research results can be rapidly commercialized 
with the principle investigators being the natural candidates to spearhead these efforts. 
Thus, university research laboratories are the foremost new entrants to the molecular 
diagnostic testing industry.  Regulations provide a modest barrier to entry as research 
laboratories do not routinely follow GLP; however, with a modest investment these 
laboratories can adapt their operations within a few months.  Still incumbent laboratories 
likely have the advantage over these players as they possess the infrastructure and 
expertise to quickly provide service on a broad scale and thus can pick and choose the 
most commercially attractive prospects. Strong intellectual property (IP) offers the 
greatest advantage for entrants; however, without the tacit operational, marketing and 
distribution capabilities of the incumbent players, they are likely to be limited in their 
reach. 
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Summary:  Rapid progress in genomic research is having a disruptive impact on 
the diagnostic industry. The new genetic tests that are emerging from this work represent 
tremendous growth potential for the entire industry which is attracting new players. At 
the same time regulators and healthcare providers are struggling to keep up even though 
it is the needs of these players that will drive the future of this technology.  Healthy 
competition among suppliers has equipped clinical laboratories with high quality 
affordable technologies that have now made it possible to meet some of these needs (i.e. 
quality, speed and cost); however the appropriate clinical application of this technology is 
not always clear and uptake by the medical profession can be unpredictable.  The current 
selection of clinically utilized molecular diagnostic tests is primarily focused on 
infectious disease, cancer and inherited diseases, with pharmacogenomic applications 
being relatively rare.  The relatively slow induction of pharmacogenomics into the clinic 
likely reflects inertia within the industry as drugs have been introduced into the market 
without the benefit of tests to predict how patients are likely to react for centuries. 
Pharmaceutical companies, regulators and physicians alike have come to accept the risks 
associated with differential drug response; however, the concept of personalized 
medicine has been discussed in the literature for many years and is now gaining 
acceptance in these quarters. As such, pharmacogenomic testing is positioned to displace 
the current standards of care in many cases.  As the knowledge base grows, 
pharmacogenetic applications have the potential to become the next great growth area of 
molecular diagnostic.  The present dearth of services in this field presents an exciting 
opportunity for forward looking laboratories to lead the way. 
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3:  THE OPPORTUITY 
The opportunities in molecular diagnostics are extensive.  With approximately 
three billion base pairs encoding the 20 to 25 thousand genes in the human genome 
(Human Genome Program, 2008), the possibilities seem endless. In fact the field is even 
greater, as these methods extend beyond human DNA to the multitude of pathogens that 
plague humanity. As previously mentioned, it has been the treaters of infectious disease 
that have led the way with this technology.  Human applications are emerging more 
slowly. 
With respect to the human genome, there are two general clinical applications; 
diagnosis or prognosis of genetic disease and prediction of response to drug therapy.  It is 
the former that has received the most attention in the research and medical communities 
with over 1500 tests now available to serve that need.  In contrast, there have only been a 
few molecular diagnostic tests applied in the clinic to pre-assess patients’ likely response 
to drug therapy.  Thus the clinical potential of pharmacogenomics has yet to be realized.  
It is this untapped market that the molecular diagnostic laboratory and Children’s and 
Women’s Hospital proposes to enter. 
3.1 Pharmacogenomics/Pharmacogenetics 
Pharmacogenomics and pharmacogenetics are two interchangeable terms used to 
describe the study of the genetic differences that explain why individuals respond 
differently to different medications.  While differential drug responses are well known, it 
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is only recently that science has advanced to the point where we are beginning to 
understand the fundamental reasons for many these differences with at least part of the 
answer being found in the DNA. Furthermore, it is possible to rapidly and to cheaply test 
an individual’s genetic profile to predetermine how, or even if certain drugs should be 
used for that patient.  Diagnostic pharmacogenomic testing as such is one of the pillars of 
the so-called “personalized medicine” paradigm (Wie H-G, 2005) which is the holds out 
the promise of improved patient outcomes and reduced healthcare costs. 
The objective of clinical pharmacogenomic testing is to maximize the efficacy of 
the drug treatment while minimizing the potential for adverse drug reactions (ADR).  It is 
the prevention of the latter, which will be the initial focus of the proposed program.  
Curtailing ADRs is of particular importance in healthcare management from both ethical 
and an economic perspective.  They are not only responsible for over 100,000 
unnecessary deaths in the United States each year, but they are also estimated to account 
for six to seven percent of all hospital admissions and/or extended hospital stays with 
associated costs likely exceeding $100 US billion (Eichelbamum M, 2006; White JT, 
1999). Although similar statistics are not available for Canada the impact of ADR is 
expected to be proportional to the population, and pharmacogenomic testing holds the 
promise of mitigating both the personal and economic costs of these reactions. 
In spite of its tremendous potential, there are currently little more than a handful 
of medications where the science supports the practical application of clinical 
pharmacogenomic testing. In fact, there only six drugs on the market with FDA 
recommendations for pre-therapy testing to assess the risk of ADRs.  They are: 
Azathioprine (leukemia), Warfarin (anticoagulant), Irinotecan (colon cancer), Valproic 
 15 
Acid (anticonvulsant), Rasbuicase (plasma uric acid management), and Carbamazepine 
(anticonvulsant, mood stabilizer) (US Food and Drug Administration, 2008). As far as 
the Author is aware, there are currently no public laboratories within Canada offering 
routine clinical pharmacogenomic testing for these medications1.  This is an oversight 
that places both the health of patients and the integrity of the provincial healthcare system 
at risk.  This proposal is the first step in addressing this issue. 
An analysis of all the appropriate candidates for pharmacogenomic testing is 
beyond the scope of this report.  Therefore the analysis will focus on only one drug, 
carbamazepine, for which there is significant medical evidence to support the 
introduction of pharmacogenomic testing at this time (see section 3.2).  However, the 
long term goal of the molecular genetics laboratory at Children’s and Women’s hospital 
is to expand this program to include all suitable drug candidates when it becomes 
appropriate.  Therefore, the analysis and recommendations within this report should be 
considered as part of a more expansive vision, even though specific guidelines focus 
specifically on pharmacogenomic testing for carbamazepine. 
3.2 Carbamazepine 
Carbamazepine is a potent suppressant of central nervous system (CNS) activity 
which is approved for the treatment of epilepsy (partial and grand mal seizures), bipolar 
disorder (acute mania and prophylaxis), and trigeminal neuralgia (severe sensitivity in the 
facial nerves) (Canadian Pharmacists Association, 2004) and is also used off label for 
                                                 
 
1 Based on personal communication with Drs Casey and Carleton. 
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other neuropathic pain2. The drug has been in use for over 30 years and is currently sold 
in Canada under the Tegretol® brand (Novartis Pharmaceuticals) as well as under 12 
different generic monikers (Health Canada, 2008) (e.g.Apo-Carbamazepine, Gen-
Carbamazepine, Novo-Carbamaz, etc). In spite of its benefits, use of carbamazepine can 
give rise to a number of side effects associated with central nervous system such as 
drowsiness, headaches, dizziness etc. While uncomfortable, these effects are not 
generally serious and are usually short-lived.  Of much greater concern are the rare yet 
potentially deadly allergic skin reactions of Steven Johnson Syndrome (SJS) and Toxic 
Epidermal Necrolysis (TEN) which have been link to carbamazepine use (Mockenhaupt 
M, 2000; Tennis P, 1997) and usually occur within the first 60 days of therapy. Both SJS 
and TEN are gruesome afflictions that are characterized by detachment of the skin and 
also affect the mucous membranes of the mouth, genitalia and the eyes. Approximately 
10% and 45% of cases respectively result in death (Warnock & Morris, 2003).  Generally 
TEN is simply a more extensive form of SJS affecting a larger surface area of the body 
(i.e. less than 15% for SJS, 15-30% for SJS/TEN and greater than 30% for TEN).  While 
the risk is remote, the consequences of SJS and TEN are devastating (see Figure 1) and 
there is a human imperative to further reduce or eliminate the risk entirely.  Fortunately, a 
pharmacogenomic solution is available – at least to some patients. 
Recently, researchers in Taiwan published the results of a study on 44 patients 
suffering from carbamazepine-induced SJS and/or TEN, and found that all of them 
exhibited a unique genetic feature in a gene encoding immune functionality called 
                                                 
 
2 Based on interviews with five neurologists 
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Currently, there is no system in place to provide at-risk British Columbians with 
HLA-B genotyping prior to carbamazepine therapy.  In fact, there is a general gap in 
provincial healthcare services with respect to pharmacogenomic testing primarily due to 
the absence of mandate.  That is, while there are a number of organizations dedicated to 
researching pharmacogenetics, there is no centre dedicated to introducing the technology 
into the clinic.  The one exception is the BC Centre for Excellence in HIV/AIDS at St. 
Paul’s Hospital which is currently routinely providing HLA genotyping for all patients 
being considered for the HIV drug abacavir, which can also cause a fatal allergic 
response in some patients.  However, that organization is dedicated to the treatment of 
HIV and is therefore limited in its focus.  On the other hand, the molecular diagnostic 
laboratory at Children’s and Women’s Hospital is a more generalized laboratory 
operation and would be an ideal locale for establishing a provincial program for clinical 
pharmacogenomic testing. 
3.3 Cost/Benefit Analysis 
While the humanitarian reasons for pharmacogenomic testing for the risk of 
SJS/TEN is unquestionable, it is nevertheless important to determine how the 
introduction of such testing will affect the healthcare costs.  Funding for healthcare is 
always challenging and often, tradeoffs between competing interests must be considered.  
It becomes important to assess the economic impact caused by the introduction of 
pharmacogenomic testing for all high risk patients starting carbamazepine therapy. 
Ideally, the carbamazepine sensitivity genotyping program would pay for itself by 
averting hospitalization costs due to SJS and/or TEN; however, both these reactions are 
exceedingly rare. While there are approximately 100 drugs known to cause these 
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reactions (Mittmann N, 2004), the combined population incidence is estimated to be only 
2 to 4 cases per million people per year (Ghislain P-D, 2008). This translates to between 
62 and 124 cases annually in all of Canada with only 8 to 16 cases occurring in BC; 
however, carbamazepine use likely contributes significantly to those numbers.  In the 
Han-Chinese population, the incidence of carbamazepine induced SJS/TEN is estimated 
to be as high as 0.25% (Hung, Chung, & Chen, 2005) among new users of the drug which 
translates to approximately 2 cases per year in BC. Of note, it is likely that all these 
estimates err on the low side as studies suggest that cases of SJS and TEN are 
significantly underreported (Mittmann N, 2004).  Thus the incidence may be higher than 
suggested here. 
The cost of a case of SJS or TEN is not insignificant as these adverse drug 
reactions are treated in the same way as severe burns. Based on data from three burn care 
units in the US, it was determined the average cost of treating a case of TEN to be 
approximately $28,000 while the cost of SJS was $14,538 (Kagan RJ, 2007).  While there 
are no comparable domestic studies, these costs are consistent with a recent report on the 
average Canadian cost of burn care treatment which was stated to be an average of 
$23,000 per patient (Canadian Institute of Health Information, 2008).  Based on this 
figure, if the carbamazepine sensitivity genotyping program averted just one case of 
SJS/TEN in BC each year, this would cover all new costs associated with testing (see 
section 6.3.2).  Furthermore, the saving are likely to be much greater than suggested as 
these calculations only account for the immediate costs of care and ignore downstream 
costs necessitated by the severe damage SJS/TEN inflicts on it victims. 
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While it is certainly important to control costs, there are many other compelling 
arguments in favour of  implementation of such a program including:  
1. Humanitarian – carbamazepine- induced skin reactions are devastating to the 
victims and usually afflict the most vulnerable in our society (children, elderly, 
mentally ill). 
2. Legal Liability – failure to comply with Health Canada recommendations expose 
the province to legal action. 
3. Goodwill – this is a modest program with a small amount of testing anticipated.  
With a relatively modest investment, the province can be seen to be providing 
patients of British Columbia with the best that healthcare has to offer. 
4. Strategic Objectives – Program fits with the strategic objectives of the Canadian 
Pharmacogenomics Network for Drug Safety (see section 4.1).   
5. Commercial Opportunity – if the program is established quickly, there may be an 
opportunity to offer this testing to other provinces for a fee.  This model was 
successfully implemented by the BC Centre for Excellence in HIV/AIDS with its 
drug resistance testing program which is still generating revenue for the Centre 
after more than eight years.  The out of province sales could generate enough 
revenues to cover all direct costs associated with the BC program, and may 
generate profits. 
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4:  RESOURCES AD CAPABILITIES 
Successful translation of the latest pharmacogenomics research into viable clinical 
services will be by no means trivial.  Not only will it be necessary to possess the 
considerable resources and organizational capabilities required to process patient 
specimens into diagnostic results in a manner that is compliant with regulatory oversight, 
it will also be crucial to effectively meld the relatively complicated science with the 
clinical and systemic needs to produce something that is understandable and useful. That 
is, this is an extremely knowledge intensive field and there is a significant knowledge gap 
within the healthcare community which developers will have to fill.  Successful 
navigation of this arena will require a cross-disciplinary perspective of multiple fields 
including but not limited to: molecular biology, biology and genetics, medicine (multiple 
specialties), pharmacology, epidemiology, pharmacoeconomics, marketing and public 
and social policy. Organizations that are best able to interpret this complex web of 
knowledge will be most likely to prosper. 
4.1 The Laboratory 
The Molecular Diagnostics Laboratory at Children’s and Women’s Hospital in 
Vancouver, is the primary provider of genotyping services to healthcare professionals 
throughout British Columba.  It is an accredited (Diagnostic Accreditation Program of the 
British Columbia College of Physicians and Surgeons), full equipped facility that 
performs more than 5000 genotype tests per year for 42 distinct genetic diseases and 
conditions (e.g. haemophilia, muscular dystrophy, cystic fibrosis). As such, it houses the 
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infrastructure, technology and expertise necessary to deliver analogous 
pharmacogenomic services to the province. 
In addition, Children’s and Women’s Hospital has been chosen as the hub of a 
nation-wide research initiative called the Canadian Pharmacogenomics Network for Drug 
Safety (CPNDS) which will be committed to accelerating the translation of 
pharmacogenomics research of ADRs (Genome British Columbia, 2008) to the clinic.  
The mandate of this organization ranges from the discovery and validation of genetic 
markers of ADRs, to the commercialization of the technology and includes all associated 
activities such as the education of stakeholders and formulation of guidelines and policy. 
The CPNDS is an extension of a previously developed clinical surveillance program 
designed to identify and recruit patients suffering from ADRs across the country. As such 
the program will leverage a well developed network of top scientists and medical 
professionals offering access to some of the most important opinion leaders in the 
country.  In addition, the CPNDS initiative will also have access to the resources of its 
partners in government (including regulators) and the pharmaceutical industry. The 
diagnostic laboratory at Children’s and Women’s Hospital plays a key role in this 
program as the pilot site for the commercialization of all new advancements emerging 
from this initiative.  As such it will be operating at the leading edge of knowledge, 
technology and medical policy, placing it in the best position for the timely provision of 
pharmacogenomic genotyping services. 
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4.2 The Team 
Dr. Brett Casey 
Director, Molecular Diagnostic Laboratory, Children's & Women's Health Centre of 
British Columbia 
Dr. Casey is a pioneer in clinical pathology, being one of the first physicians on 
the continent to combine his pathology training with clinical molecular diagnostics.  
Since finishing his residency in the latter, he has been a leader in bringing molecular 
diagnostics to the mainstream through his research and clinical activities.  He currently 
wears a number of hats including: Assistant Professor at the University of British 
Columbia where he carries on an active research program focus on genetic birth defects, 
Director of Molecular Diagnostics at Women & Children’s Hospital in Vancouver and a 
member of the Scientific Advisory Committee for the CPNDS.  Dr. Casey will 
responsible for all medical activities associated with the clinical pharmacokinetics 
program. 
Dr. Bruce Carleton 
Director of Pharmaceutical Innovations Program, Children’s and Women’s Health 
Centre of British Columbia 
Dr Carleton is a full Professor in the Faculty of Pharmaceutical Science at the 
University of British Columbia where he leads an active pharmacogenomics research 
program focused on managing adverse drug reaction in paediatric patients.  He also 
serves as the Director of Pharmaceutical Innovations Program at Children’s at Women’s 
Hospital in Vancouver that functions to address the multiple needs of governments 
attempting to manage drug budgets, clinicians attempting to improve patient care, and the 
public who demand safe, effective and cost efficient drug programs. In this capacity Dr 
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Carleton is an opinion leader at both the level of the clinical and public policy. Dr. 
Carleton is also a project leader for Genome Canada’s Genotype-specific Approaches to 
Therapy in Childhood (GATC) program and co-leader of the CPNDS. 
4.3 Summary 
With two of the most preeminent experts in the country leading the way and a 
fully equipped laboratory with a proven track record of providing this type of service, the 
molecular diagnostic laboratory at Children’s and Women’s Hospital is the ideal location 
for British Columbia’s pharmacogenetics program.  There is no doubt that this Centre 
harbours all the scientific, medical and operational resources and expertise necessary to 
meet the needs of such a program, and, in its association with the CPNDS, the laboratory 
has access to leading medical and scientific institutions and opinion leaders nation-wide 
which will allow it to stay ahead of curve well into the future. With the right strategic 
plan the laboratory should be able to establish itself as a translational leader, assuring that 
the most appropriate breakthrough in pharmacogenetics are delivered to the patients of 
British Columbia and Canada in a timely and cost efficient manner. 
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5:  MARKET RESEARCH AD AALYSIS 
5.1 Overview 
The market for any diagnostic medical services or products is highly complex and 
variable with multiple stakeholders.  While the ultimate beneficiaries are the patients, it is 
physicians who are the gate keepers, and in Canada, it is the agencies of provincial 
governments that pay for these services.  The nature of patient cohorts and care providers 
can vary significantly depending on the indication for the diagnostic service as can the 
disposition of the payer to pay.  For example, the decision making process for a 
neurologist treating an epilepsy patient in private practice is likely to be different from 
that of a salaried psychiatrist treating bipolar disorder in a hospital ward. In addition to 
the different clinical considerations, reimbursement concerns will vary as payment for 
services are likely to come from a provincial health insurance plan in the first case and 
from a global hospital budget in the latter.  Payment decision makers will likely have 
different priorities in these two cases.  The picture becomes even more convoluted as 
each provincial jurisdiction will have its own set of players with different interests.  
Furthermore, in the case of pharmacogenomics, the regulatory agencies and 
pharmaceutical companies may also play a role depending on the associated risks and 
benefits. Given this complex web of players, considerable finesse is required to 
successfully launch a new diagnostic service.  The market for HLA-B genotyping to 
inform carbamazepine therapy will be no exception.  
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As previously discussed, carbamazepine is indicated for epilepsy, neuropathic 
pain and mood disorders; however interviews with physicians suggested that it is 
primarily prescribed to treat the first two and only rarely for the latter.  Epilepsy and 
neuropathic pain are normally managed by neurologists and there are reportedly 733 of 
these in the country (Canadian Medical Association, 2008) with approximately 60 
specializing in treatment of epilepsy (Theodore, et al., 2006).  The corresponding counts 
in British Columbia are 109 and 10.  Although epilepsy is generally diagnosed before the 
age of 18 (i.e. approximately 80% of the 15,500 annual new cases in Canada), 
carbamazepine is generally reserved for adults (see Table 1 below).  The incidence of 
neuropathic pain on the other hand generally increases with age with the vast majority of 
cases occurring in patients over 45 (Hall, Carroll, Parry, & McQuay, 2006). Thus, the 
most typical scenario which would lead to utilization of carbamazepine sensitivity testing 
would involve a neurologist, in an office setting, prescribing carbamazepine for the first 
time to an adult patients suffering from epilepsy or neuropathic pain. 
While care providers for the mentally ill are a much smaller consumer group, they 
may turn out to be enthusiastic users of an HLA-B genotyping service because of the 
vulnerability of their patient population.  Carbamazepine is normally used as a second 
line therapy for hard-to-treat cases of bipolar disorder or in rare cases, for the treatment of 
manic episodes in a hospital setting (Goodwin, 2003; Sach, Printz, Kahn, Carpenter, & 
Docherty, 2000). Under these circumstances, the prescribing physician is most likely to 
be one of 4200 psychiatrists in the country; or in BC, one of 650 (Canadian Medical 
Association, 2008).  Thus, the typical scenario for accessing the test in this context would 
involve a psychiatrist prescribing the carbamazepine for the first time to an adult patient 
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in order to manage ongoing therapy or to control a manic episode in either a hospital or 
private practice setting.  Of importance, there is a significant overlap between mental 
illness and epilepsy which creates a channel between the different types of practitioners.  
While the total number of practicing neurologists and psychiatrist in the country is 
sizable, marketing efforts need only concentrate of a few major Centres as over 80% of 
the appropriate ethnic populations live in one of six cities. Listed in order of decreasing 
population density they are: Toronto, Vancouver, Montreal, Calgary, Edmonton and 
Ottawa (Statistics Canada, 2008). Toronto and Vancouver alone are home to over 65% of 
this cohort and therefore initial marketing efforts should concentrate on appropriate 
practitioners in these two cities. 
5.2 Total Market Size 
The total market size for HLA-B genotyping program is defined by the number of 
patients of Han Chinese heritage that are prescribed carbamazepine for the first time (i.e. 
carbamazepine naive) for any reason in any given year.  These are the only patients for 
whom the HLA-B genotyping test would be of value.  To estimate this, the databases of 
the private healthcare research organization, Brogan Inc. were consulted for all new 
(incident) carbamazepine prescriptions and the proportion of patients that were in high-
risk group was estimated using Canadian census data (Satisitcs Canada, 2008).  The final 
results of these calculations are provided in Table 1and Table 2 for British Columbia and 
the rest of Canada respectively.  The strengths, limitations and implications of these 
estimates are discussed below. 
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Table 1: Estimated annual number of carbamazepine naive patients of Han Chinese 
descent initiating carbamazepine therapy in British Columbia.  
 2003 2004 2005 2006 2007 Average 
Under 19 49 32 37 34 39 38 
19 and up 970 766 811 821 959 865 
Total 1,019 798 848 854 998 904 
Derived from Brogan Data (Appendix A) and 2006 Canadian census data (Statistics Canada, 2008). 
Table 2: Estimated annual number of carbamazepine naive patients of Han Chinese 
descent initiating carbamazepine therapy in the rest of Canada. 
 2003 2004 2005 2006 2007 Average 
Alberta 459 394 396 429 404 416 
Saskatchewan 23 25 25 22 22 23 
Manitoba 80 67 75 74 73 74 
Ontario 1,167 1,230 1,141 1,027 998 1,113 
Quebec 67 63 60 58 60 62 
Maritimes 20 21 18 21 17 19 
Rest of Canada 1,,816 1,800 1,715 1,631 1,574 1,707 
Derived from Brogan Data (Appendix A) and 2006 Canadian census data (Statistics Canada, 2008). 
Brogan Inc is a private research company specializing in healthcare intelligence 
services which compiles data provided by a selection of private health insurance 
companies across the country. For the purpose of this report, Brogan was contracted to 
query its database for patients newly prescribed carbamazepine therapy (carbamazepine 
naive) each year between 2003 and 2007 stratified by region, age (younger than 19 vs. 19 
and older) and gender (Appendix A).  Patients were assumed to be carbamazepine naive 
if they had not received the drug in the year preceding their first claim. Final total 
carbamazepine utilization estimates were obtained by adjusting for the estimated capture 
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rate defined as the percentage of the population represented by the data for each region 
(Appendix A). 
Based on the Brogan data, the estimated average total number of patients newly 
prescribed carbamazepine therapy on an annual basis was approximately 6,700 and 
30,800 for BC and the rest of Canada respectively. This means that 16 out of every 
10,000 people in BC take their first dose of carbamazepine each year while the 
corresponding rate in the rest of Canada is 10 out of 10,000. Please note, these rates seem 
high when compared to those reported in other countries.  For example researchers in 
each of Germany (Mockenhaupt M, 2000), the Netherlands (Tsiropoulos B, 2006) and 
Demark (Knoester PD, 2004)  reported incident carbamazepine use to be 9, 2.5 and 4 per 
10,000 per year respectively.  On the other hand, drug utilization can vary significantly 
between jurisdictions, and over time and therefore it is difficult to draw conclusions from 
these differences.  In the absence of more direct evidence, the estimates derived from the 
Brogan database were used without modification. 
The annual number of at-risk carbamazepine naive patients was estimated by 
adjusting the total naive carbamazepine utilization estimates by the proportion of the 
population represented by at-risk groups using the 2006 Canadian census data (Appendix 
B).  At-risk groups were defined as nationalities identified in the US FDA warning of 
December 2007 with the exception of East Indians.  The latter were excluded because 
Health Canada does not refer to these or any other nationalities in its warnings (Health 
Canada, 2008) but rather only to “patients of Asian– particularly of Han Chinese  
ancestry.”  Furthermore, the literature to date has only identified individuals of Han 
Chinese descent harbouring the HLA-B polymorphisms as being at-risk and therefore, 
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only regions where a significant proportion of the population meets this description are 
included in this analysis.  It should be noted that the final decision of which patients to 
include in the program is a policy decision that should be driven by the medical 
community and not by the Author. 
Thus the number of patients eligible for HLA-B genotyping to manage 
carbamazepine therapy is approximately 900 and 1700 for BC and the rest of Canada 
respectively.  This translates to a maximum weekly demand of 49 tests nation - wide; 17 
for British Columbia and 32 for the rest of the country.  Clearly the potential Canadian 
market for HLA-B genotyping to inform carbamazepine therapy is relatively modest.   
Based on current pricing standards for a similar test for abacavir therapy (John Hopkins, 
2008; Veenstra, 2004; United States Department of Veterans Affairs, 2008), the price of 
the proposed test would likely be limited to approximately $100 leaving the size of the 
entire Canadian market at $260,000.  Because the intent is to provide this service for free 
for patients in British Columbia, the total annual revenue potential for the rest of Canada 
is $170,000. 
5.3 Determinants of Demand 
The total size of a market is generally not a good indication of demand - 
especially for newer technologies.  During the early stages of its lifecycle, the uptake of a 
new product or service is usually slow and without a concerted marketing effort can stay 
that way.  Good marketers understand this and begin planning their marketing strategies 
during the conceptual stage of design and continue their efforts throughout the product 
lifecycle. 
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Probably the most important determinant of demand is the consumers need (or 
desire for the product/service offering. If it is difficult to convey the benefit, it will be 
difficult to sell. Even when the offering is beneficial, it takes time for consumers to 
become aware and develop enough of an interest to pursue information about the benefits 
before becoming convinced that it is worth adopting and buying in. Different consumers 
advance through the process at different rates depending upon their level of involvement 
and it is important when bringing a new product of service to the market to understand 
these factors.  It is therefore instructive to examine who the consumers are, their 
motivation and their decision making processes. In turn, this exercise will assist in the 
development of a marketing plan by identifying market segments with the most 
motivation to adopt a new technology and therefore the most amenable to marketing 
efforts.  Finally it is important to understand the competitive landscape to plan for 
differentiation of the offering in order to maximize market share.  These issues and how 
they relate to the proposed program of HLA-B genotype testing for carbamazepine 
sensitivity are discussed in this section. 
Buyer Behaviour  
As previously discussed, there are a number of players in the market with an 
interest in HLA-B genotyping; however, physicians are probably the most important with 
respect to marketing efforts.  Not only are they the decision makers in the purchasing 
process but they are also essential to lobby provincial health authorities to pay for new 
medical services.  As a whole, physicians are an extremely demanding when considering 
new technologies for the clinic and the burden of proof is high; however, this can be 
tempered by the perception of need. 
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Modern medicine is evidence-based with statistically significant prospective 
clinical trials being the highest standard of evidence, followed by retrospective studies 
and finally anecdotal evidence.  Generally speaking, the profession will follow medical 
protocols that have been established in prospective clinical trials first and will experiment 
with new ideas and procedures only when those fail, do not exist, or as part of well 
controlled clinical trials. However, when a new treatment option comes with little risk 
(i.e. it does no harm) and there is at least retrospective evidence of its value, there is more 
freedom to experiment with new treatment options – or not, depending on the judgement 
of the treating physician.  Thus the decision to adopt a new medical option comes down 
to a risk/benefit analysis based on the strength of the medical evidence and the clinical 
imperative.  If the profession as a whole has not passed judgment, then the decision is left 
to the discretion of the treating physician. 
 In the case of carbamazepine, the new treatment option is to adopt, or not to 
adopt a harmless new test in order to avoid a very rare, but very serious adverse reaction 
to a drug that has been used for decades.  Under these circumstances, both the perception 
of need and the burden of proof will be somewhat subjective.  Other issues such as the 
convenience of the service and the impact on the course of patient care will weigh 
heavily on the decision.  Each of these issues is discussed below with respect to the 
factors influencing physician perceptions of HLA-B genotype testing for carbamazepine 
sensitivity. 
The perceived need of the HLA-B genotyping test 
Carbamazepine has been used in clinical practice in Canada for over thirty years 
without the benefit of an HLA-B genotyping tests and it is likely that most physicians 
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have not experienced an advanced case of SJS and/or TEN in that time.  Indeed, two 
physicians interviewed for this analysis each reported experiencing only one possible 
case of SJS/TEN in their careers (30 years in one case) and in both cases, the severity of 
the reaction was mitigated by immediately discontinuing therapy (although both patients 
were hospitalized).  The current standard of care involves advising patients new to 
carbamazepine to monitor themselves for skin reactions for the first 60 days of therapy 
and to discontinue the drug if a rash is detected. If experienced physicians have 
successfully managed care by this method for years, it might be difficult convincing them 
that the test is needed.  Indeed one neurologist in BC interviewed for this study expressed 
the opinion that the test would be a “waste of money.” 
On the other hand there are clinical scenarios where physicians may perceive the 
need.  Inexperience with carbamazepine, previous bad experience with SJS/TEN, a high 
proportion of Han-Chinese patients in their clinical practice or lower functioning patients 
(i.e. unable to monitor themselves for skin rash) may be enough to induce physicians to 
utilize the test.  Given that the SJS/TEN can be fatal, it is expected that some physicians 
would ‘just rather not take the chance.’ In fact at least two neurologists and two 
psychiatrists practicing in the province suggested they would likely use the test if and 
when it became available. 
Of interest, the advisories issued by Health Canada and the FDA coupled with the 
inclusion of this information on the product monographs may have created a need as 
these announcements have created a potential for legal action if the test is not utilized.  
Regardless of the legal merit of the argument, it is an eventuality that many physicians 
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would usually prefer to avoid.  Therefore, some might choose to access the test for legal 
rather than clinical peace of mind. 
Perceptions of “the proof” for HLA-B genotyping 
To date the evidence for the test is based on retrospective studies, which is less 
than ideal.  A randomized clinical trial that demonstrated that patient outcomes were 
better when the test was utilized in managing therapy versus when it was not would be 
more convincing; however, such a trial is unlikely to be undertaken in any meaningful 
way because the number of Han-Chinese carbamazepine patients is low and SJS/TEN is 
so rare.  Such a trial would require an enormous sample size and would be extremely 
challenging; at least in this part of the world.  However, the retrospective data is quite 
compelling and there is a general consensus in the scientific and healthcare communities 
that the association between these skin reactions and the HLA-B polymorphism in Han-
Chinese patients is very real (Health Canada, 2008; US Food and Drug Administration, 
2007; Ingelman-Sundberg, 2008; Depondt, 2008).  Given the benign nature of the test, it 
is unlikely that it will be rejected because it hasn’t met the burden of proof. 
The perceived convenience of HLA-B genotyping. 
Like most professionals, physicians have limited time and generally do not readily 
tolerate new technologies if they cannot be easily integrated into their practices.  If a new 
test requires extra time, money and/or effort on the part of the physician, then the need 
and/or the burden of proof for the test will be higher.  Although accessing and 
interpreting tests for carbamazepine sensitivity will be simple, the test will necessitate an 
extra visit by the patient to the doctor’s office, thus increasing the physician’s workload. 
This might be a good thing if the doctor works on a fee for service basis; however, it 
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would be a burden if he/she is salaried.  In reality this is not likely to be a significant 
issue in the minds of most neurologists.  With over 40 working in the Greater Vancouver 
area, the average physician would have to accommodate an extra 22 extra patient visits a 
year (assuming all 900 eligible patients in the province are referred for testing) which 
translates to approximately six extra minutes per week or a 0.2% increase in the median 
48.4 patient care hours worked per week (Freeman, 2003). 
The perceived clinical value of HLA-B genotyping 
Diagnostic and prognostic tests are used as part of the clinical decision making 
process and it is important from a physicians perspective to know if and how clinical 
action will be altered by the new information.  Many medical conditions detectable by 
molecular diagnostic tests are not treatable and may only serve to answer questions or 
inform clinical monitoring decisions.  Generally speaking, pharmacogenetic results offer 
more clinical options as physicians can choose to alter the dose (or dose frequency), 
select alternative drugs or simply monitor response more closely.  It is important to know 
how HLA-B testing for carbamazepine-induced SJS/TEN will alter clinical options. 
Current data (Hung, Chung, & Chen, 2005) suggest that, within the Han-Chinese 
population, 8% of individuals testing positive for the carbamazepine sensitive genotype 
will develop SJS and/or TEN if given carbamazepine whereas those testing negative have 
no chance of this adverse reaction.  Given a positive result, physicians can choose to 
avoid carbamazepine altogether and choose one of many other available drugs (at least 12 
for epilepsy, six for bipolar disorder and four for trigeminal neuralgia) or monitor the 
patients more closely for skin reactions.  If the patient test negative, physicians can 
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manage the therapy as normal.  Thus, the proposed test appears to have some merit 
providing actionable information in some cases and peace of mind for others.  
Summary 
For physicians, the decision to bring a new diagnostic test to clinical practice can 
be very involved. They are obligated to provide the best care for their patients; however 
they need proof that changes are going to help.  Generally they tend to look to opinion 
leaders/experts to gather the necessary supportive evidence and come to a consensus on 
how the technology should be introduced into care. For truly superior advances, positive 
recommendations represent a leap across the market ‘chasm’ and generally the 
technology will be rapidly taken up by the early and late majority alike.  When the impact 
of a new technology is more modest, recommendations can be more equivocal and 
vendors must work this market like any other seeking out champions in strategic sectors 
and work those sectors until they can gain a foothold.  Peer to peer recommendations are 
probably more important under these circumstances. 
The potential for consensus on testing for carbamazepine sensitivity is uncertain.  
Based on interviews with three neurologists and two psychiatrists there has been very 
little debate occurring within the medical community since the original recommendations 
were issue by the FDA last December.  This is likely because without an available test, 
the discussion would be purely academic.  It is likely that the introduction of the test will 
initiate some debate based on opinions expressed by physicians interviewed which 
ranged from: 
 “the test is a waste of money”  
 to 
 37 
“I think it is an issue that is generally being ignored by the 'eurology community, and is 
particularly relevant in a place like Vancouver with a higher Chinese population. They 
don't view a rash as a big deal, but I have seen horrendous cases of S-J Syndrome and 
Toxic Epidermal 'ecrolysis.  I think the data for testing in the Chinese community is 
compelling and with so many other drug options for epilepsy or neuropathic pain, it 
should be done.” 
Of note, only one out of seven of the medical professionals interviewed was 
opposed to the idea of carbamazepine sensitivity testing; although only a few had given 
the issue much consideration.  The opposing voice was that of a neurologist who was a 
specialist in epilepsy with over thirty years experience who might have had some status 
as an opinion leader among local practitioners. In any case, there are strong arguments on 
both sides of the issue (Table 3) and until the there is a consensus, HLA-B genotyping for 
carbamazepine will not become a standard of care and will remain up to the discretion of 
the individual physician. 
5.1 Segmentation and Targeting 
Consumers of healthcare products and services can be segmented by a several 
criteria. In Canada the market is first segmented geographically by province and 
territories which means dealing with at least 11 separate jurisdictions.  Within each 
province the market can be further broken down by health authorities, disease, medical 
specialities, organizational structure (hospital vs. private practice), and finally physician  
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Table 3: Incentives and Disincentives for HLA-B genotype testing to manage 
carbamazepine therapy 
For Against 
• SJS/TEN can be fatal (30 to 40% of 
cases result in death) 
• Risk of SJS/TEN 10-fold higher in Han-
Chinese patients (1 in 400) 
• Carbamazepine – induced cases in 
SJS/TEN are very rare. (2 to 4 in 10,000) 
• Genotype association with SJS/TEN 
very strong in retrospective studies. 
• Value of test has not been demonstrated 
in prospective clinical trial 
• Many physicians inexperienced with 
carbamazepine 
• Low functioning patient may not be able 
to reliably monitor themselves for rash. 
• Carbamazepine has been used for 
decades without such a test. 
•  SJS/TEN can be avoided by monitoring 
for rash – easy for high functioning 
patients. 
• Absolute negative predictive value – 
provides some peace of mind 
• Marginal positive predictive value of the 
test (7.7%). 
• Test will be easy to access (free to BC). • Rest of Canada: cost of test is not 
covered. 
• Health Canada and FDA all recommend 
pre-therapy HLA-B testing. 
• Regulatory agencies have no authority 
over physicians 
• Ignoring recommendations raise 
potential for malpractice suit. 
• Merit of malpractice cases would be 
questionable 
and patient demographics. Figure 4 illustrates the higher level segments of the market for 
an HLA-B carbamazepine sensitivity test. 
Outside of British Columbia, neurologists in Ontario represent the biggest 
potential user group for the test.  This is the province with the largest Han-Chinese 
population and neurologists are the care providers that are most likely to be the first to 
 Figure 4: Hierarchy of the market segments that are potential users of HLA
genotyping test
Ontario; b) primary indication; c) primary pres
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Patient of diminished capacity are over represented in at least two of three 
patients groups indicated for carbamazepine.  For example, an estimated 23% of 
epileptics suffer from varying degrees of mental retardation and up to 18% of newly 
diagnosed patients suffer from dementia associated with stroke (Shorvon, Fish, Perucca, 
& Dodson, 2004).  Furthermore approximately 6% of epileptics suffer from severe 
psychiatric disorders (Shorvon, Fish, Perucca, & Dodson, 2004) with up to 50% suffer 
from mood disorders (Kanner, 2007). In patients with bipolar disorder, carbamazepine is 
used as a mood stabilizer and for manic episodes. While treatment can restore 
functionality, these patients are by definition operating at diminished capacity at 
treatment initiation.  In contrast, neuropathic pain can affect all age groups (Hall, Carroll, 
Parry, & McQuay, 2006) and there is no reason to believe that prevalence of reduced 
capacity is any greater or any less in this group than the population at large - 
approximately 5% (e.g. 1% schizophrenia, 1% organic brain disorder, 1.6 % substance 
abuse, 5.8% mood disorder etc. (Arboleda-Florez, 2005)). Thus among these patient 
cohorts, there is reason to believe that genotyping for carbamazepine sensitivity would be 
of benefit at least 25% of Han-Chinese patients initiating therapy with the drug, based on 
the anticipated mental health of the patients involved. 
5.2 Competition 
Although there are currently no laboratories in British Columbia or Canada 
providing HLA-B genotyping services for carbamazepine therapy, the number of 
molecular diagnostic laboratories and/or research laboratories is considerable, raising the 
threat of competition.  Any laboratory with genotyping capabilities could establish an 
assay for this purpose within a few months.  While the logistical challenges of providing 
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such a service present a barrier, there are at least 11 Canadian molecular diagnostic 
laboratories with the operational capabilities to rapidly enter the market (National 
Institutes of Health, 2008).  In addition, some of the more generalized diagnostic 
laboratories have the capabilities to provide HLA-B genotyping with equal efficiency 
including industry giants Quest Diagnostics and LabCorp.  It will be necessary to be both 
fleet and lean in order to gain advantage in this environment. 
At this time, the major barriers delaying the introduction of HLA-B genotyping 
for carbamazepine therapy are indecision and market size.  The Canadian 
recommendations for carbamazepine sensitivity testing were issued in March of this year 
and the organizations with the capabilities to do this work need to weigh the costs, 
benefits and risks associated with such and initiative. Also, because the 
pharmacogenomics market has not completely emerged, it is likely that uncertainty exists 
in the minds of the decision makers about investing in such an effort.  Furthermore, only 
BC and Ontario have a sufficient incident of carbamazepine use among Han-Chinese 
populations large enough to justify such a program (Table 1 and Table 2) and even then, 
the test would be considered to be relatively esoteric on a provincial level.  
Ideally, a single reference laboratory would provide this service for the entire 
country allowing for the operation to capitalize on the economies of scale.  The vision of 
this proposal is to position the molecular diagnostic laboratory at Children’s and 
Women’s Hospital as the national reference laboratory for carbamazepine sensitivity 
testing.  It is anticipated that if the laboratory can be the first in the country to offer a high 
quality, cost efficient HLA-B genotyping service to inform carbamazepine therapy, it will 
capture the entire market. The BC Centre for Excellence in HIV/AIDS was successful in 
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employing this strategy 10 years ago when it became the sole provider of HIV resistance 
testing in Canada.  In order for the strategy to work, it will be important to control costs 
and strategically price the service to discourage entry. 
5.3 Estimated demand for HLA-B genotyping service carbamazepine 
sensitivity 
Definitively forecasting the demand for HLA-B genotyping for eligible 
carbamazepine patients is challenging.  Much will depend on the communications efforts 
put forth by the leaders at Children’s and Women’s Hospital and the Pharmacogenomics 
Network for Drug Safety.  While reports from other parts of the world indicate that 
clinical adoption of pharmacogenomic testing has been slow (Martin, Lewis, Smart, & 
Webster, 2006), research has shown that uptake is greatest when the service is associated 
with a strong research program (Corkindale, Ward, & McKinnon, 2007).   
To date, market uptake of other pharmacogenomic testing options has been 
erratic.  For example tests for genetic markers to predict potentially fatal mylosupression 
due to azathiopurine therapy for leukemia have been generally ignored by the medical 
community whereas genotyping for hypersensitivity to the HIV drug abacavir has been 
rapidly adopted (Alfirevic & Pirmohamed, 2008); but, only after prospective randomized 
clinical trials demonstrated a reduction in adverse reactions when genotyping was 
employed. Being a relatively new testing procedure with no supporting prospective 
clinical evidence, it is expected that the initial uptake of HLA-B genotyping for 
carbamazepine sensitivity will be slow.  Decisions are likely to be made on a case by case 
basis driven by the perceived vulnerability of the patients involved, with children, the 
mentally challenged and the mentally ill being the primary users of the service.  These 
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combined cohorts are estimated to account for at least 25% of incident carbamazepine 
use among epileptics as previously discussed (see page 40).  Early adopters and 
physicians with high Chinese patient populations are expected to be secondary drivers.  
Full uptake is not expected take place until consensus is reached among the medical 
community. 
Based on strength of the scientific evidence, the ease of access and interpretation 
of the test, the recommendations by the regulatory agencies, the potential to avert tragedy 
(and the accompanying lawsuits) and interviews with neurologists and psychiatrists, it 
conservatively predicted the HLA-B genotyping for carbamazepine sensitivity will 
eventually be adopted to manage the carbamazepine therapy of 50% of eligible patients - 
20% in the first year after launch, 35% in year two and 50% thereafter.  Because of 
logistical issues and the associated costs, uptake in the rest of Canada is expected to be 
slower with 10% accessing the test in the first year, 20% by year two and 30% thereafter.  
Assuming no other laboratories begin offering this test in that time, all this work will 
come to the molecular diagnostics laboratory at Children’s and Women’s Hospital in 
Vancouver. Based on these assumptions, the projected workload for the program is given 
in Table 4. 
5.4 Summary 
Estimates of the total number of British Columbian and Canadian patients that are 
newly prescribed carbamazepine each year combined with estimates of how many of 
those would be Han-Chinese indicates that approximately 900 and 1700 patients 
respectively would be eligible for HLA-B genotyping to predict sensitivity to the drugs 
(see Table 1 and Table 2).  Of course uptake of the test would not be 100% as at least 
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Table 4: Projected Provincial and ational demand for HLA-B genotyping for 
carbamazepine therapy in the first three years after launch 
Year Demand 
Annual (weekly) 
 
British Columbia Rest of Canada 
1 180 (3 -4) 170 (ca. 3) 
2 315 ( ca. 5) 340 (6 – 7) 
3 450 (ca. 8) 510 (ca. 10) 
4 450 (ca. 8) 510 (ca. 10) 
 
some physicians would be resistant to adopting a new test to manage a drug that they 
have been using for decades.  Until there is a professional consensus on the best 
application of the test, utilization will be discretionary; however, at least four out of seven 
prescribers of this drug suggested they would access the test if it became available with 
two others being noncommittal and the last being firmly against adoption.  Based on 
these informal results and an assessment of the pros and cons of the test, it is estimated 
that the test will eventually be adopted by at least 50% of prescribers in BC and 30% in 
the rest of Canada or 450 and 510 tests per year respectively.  These estimates are 
judgement based and it is recommended that a survey of neurologists be conducted in 
order to get a better idea of who would access the test and under what conditions. 
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6:  ECOOMICS OF THE TESTIG PROGRAM 
6.1 Overview of the Process  
The molecular diagnostics laboratory at Children’s and Women’s hospital is 
currently well established in British Columbia as the primary provider of medical genetic 
tests for physicians across the province.  As such, systems and protocols for delivering 
these services in BC are fully developed (Figure 5).  Briefly, when a physician orders a 
test, a form (designed and provided by the laboratory) is given to the patient who reports 
to the nearest hospital or commercial blood collection facility where five to ten millilitres 
of blood are collected.  The blood sample is then transported to the testing laboratory 
where it is received, labelled (i.e. numbered) and logged into the laboratory information 
system (LIS) which is designed to track the sample throughout the remaining processes.  
The blood sample is then stored until ready for DNA extraction and genotype analysis 
both of which are usually performed in batches.  Results from the test are reviewed by the 
laboratory staff and, if acceptable, will be entered into a form report (usually 
automatically).  The report is then reviewed and signed off by the laboratory medical 
director before it is packaged and mailed to the ordering physician by clerical staff.  Each 
step in the process has its associated costs; however, in this analysis only the major costs 
associated with the new carbamazepine genotyping program is examined. 
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6.2 Cost Breakdown  
As illustrated in Figure 5, diagnostic testing of blood samples requires handling 
by at least three different cost centres; blood collection, shipping and the laboratory.  The 
per sample expense of each process can vary significantly depending on the volumes 
involved, however, based on expected demand (Table 4), the average cost per sample is 
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Figure 5: Process Scheme currently employed in the provision of clinical genotyping 
service in BC 
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expected to be approximately $61 in year one (Figure 6) dropping to $49 by year three.  
The breakdown of cost is as follows. 
 
Figure 6: Functional breakdown of the average per-sample cost of providing 
eight genotype tests per week to patients in British Columbia. 
6.2.1 Blood Collection 
Introduction of carbamazepine genotyping program in most cases will necessitate 
a dedicated blood sample. It is estimated that each blood draw costs the system 
approximately $3.50 in consumables (blood tube, needle and holder, gloves, alcohol 
swab, cotton) and approximately $3.50 in labour (approximately 10 minutes of clerical 
and phlebotomy). 
6.2.2 Shipping 
Shipping can be one of the most expensive components of diagnostic services 
involving blood tubes.  In order to ensure timeliness of service and integrity of the 
samples, blood sample tubes must be shipped to the molecular diagnostics laboratory 
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within 24 hours of collections.  Within Vancouver there are cost efficient procedures in 
place for inter-hospital transport; however, it is likely that many patient samples will need 
to be shipped by courier from locations outside the hospital network.  Further, because it 
is a ‘biological’, there are rigorous packing requirements for specimens travelling 
extended distances (Harvard University, 2002). 
Thus shipping costs can range from no cost for a sample collected within the 
hospital network in downtown Vancouver to approximately $15 per sample for 
specimens transported within the greater Vancouver area and up to $35 for a sample 
collected in other parts of the province.  However, given that the majority of the Han 
Chinese population lives in the lower mainland of British Columbia, it is estimated that 
the majority of patient blood samples will be coming from this region and shipping costs 
will be minimized to a great extent by batch shipments. Thus the average specimen 
shipping cost for BC is expected to be relatively low and is estimated to be a maximum 
of $5 per sample3. 
6.2.3 Laboratory: Analytical Costs 
Processing in the laboratory is extensive and sophisticated; however the current 
technologies can be very cost efficient.  Progress in automation now enables a single 
technician to process from hundreds to thousands of patient samples a day for less than 
$10 per sample; however, the economies of scale are important in achieving this 
efficiency. Molecular diagnostic laboratories rarely work on this scale and rigorous 
                                                 
 
3 Based on personal conversation with the manager of the accessioning laboratory at Children’s and 
Women’s Hospital and private discussion with Corporate Couriers of Vancouver and list prices provided 
on FedEx.ca. 
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quality requirements imposed on diagnostic laboratories limit their ability minimize 
costs. 
Because of the stakes involved (human health and life), quality assurance in 
diagnostic laboratory is paramount and as such it is necessary to reference each 
diagnostic test result to a series of quality control samples that test the limits of the assay 
as well as all the possible results that might be observed (College of American 
Pathologists, 2007).  A valid HLA-B assay for carbamazepine would likely require a 
minimum of five control samples for each batch.  The cost of analysing each quality 
control sample would be at least as much as a patient sample and these must be included 
in each batch regardless of whether the batch involves one patient sample or one-
hundred. Approximately $8 in reagents and consumables are involved in the analysis of 
each batch unit (including controls) which means the associated per patient costs for a 
batch size of one would be $48 dollars; that is, $8 for the patient sample plus $40 for the 
controls.  In contrast, it would cost only $8.40 per sample for a batch size of 100 patient 
samples because the associated cost of controls is 1/100th of the previous example.  
Clearly it is desirable to maximize batch size as much as possible. 
Limiting the HLA-B genotyping program to British Columbia will make 
maximizing batch size challenging.  Based on the projected demand (Table 4) the 
laboratory should receive three to four samples per week from British Columbians in the 
first year growing to eight per week in the third.  In order to make the program workable 
to physicians these samples will all have to be analyzed within 5 business days.  The 
corresponding per sample costs range from $36 to $23 (including labour) for three patient 
and eight patient batches respectively.  Expanding the program to the rest of Canada is 
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predicted to raise demand to 18 tests per week (Table 4) at a cost of approximately $19 
per sample. 
6.2.4 Laboratory: Post Analytical Costs 
The last major cost associated with HLA-B genotyping is associated of with the 
medical interpretation of the results.  This requires high value time of the laboratory 
pathologist to review, troubleshoot (if necessary) and sign off on the results and is 
estimated to cost approximately $25 per sample under ideal conditions.  At higher 
throughputs, this constitutes over half the costs of all laboratory processes.  Automating 
the process as much as possible would be an effective use of resources. 
All laboratory processes and the estimated associate cost are summarized in Table 
5. By summing these estimates the total direct laboratory costs associated with a single 
test would be approximately $49 by year three based on the weekly throughput projected 
in Table 4 (i.e. 8 to 9 patients).  These do not take into account overhead cost associated 
with general laboratory operations. 
Table 5: Estimated per sample cost value associated with the laboratory processes 
involved in the delivery of an HLA-B genotyping report for carbamazepine 
sensitivity (assuming a weekly batch size of eight).1 
 Reagents Consumables Labour 
Sample Accessioning
2
   $2.00
3 
DA Extraction $2.00
4  $1.505 
Laboratory Analysis $5.50
6 $7.507 $3.008 
Verification and Report Entry   $1.00
9 
Pathologists Review   $25.00
10 
Delivery of Report  $0.50 $0.50
11 
Total $7.50 $8.00 $33.00 
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otes for Table 5 
1.  All estimates have been rounded to the nearest $0.50. 
2. Refers to receipt and cataloguing of sample. 
3. Assumes clerical effort of 5 minutes at a cost of $25 per hr (wage and benefits). 
4. Cost was based on that estimated for a robotic system reported in the literature 
(Ivanova, DeWaard, & Herber, 2006). 
5. Assumes 60 minute effort on 24 samples by a medical technologist at cost of $30 
per hr. 
6. Per reaction reagent costs were estimated as the average of three estimates 
provided by three different vendors (Applied Biosystems, Qiagen and Luminex) with 
technological platforms suitable for HLA-B genotyping (average = $3.51).  Per sample 
cost were based on a batch size of eight patient samples and five internal controls. 
7. Per reaction consumable costs were estimated by summing all the vials, test tubes, 
pipette tips etc. for a typical analytical procedure and applying the list prices given in the 
Fisher or VWR Canlab catalogues (ca. $4.50 total).  Per sample cost were based on a 
batch size of eight patient samples and five internal controls. 
8. Assumes 40 minutes effort on seven samples by a medical technologist at a cost 
of $30 per hour. 
9.  Assumes 15 minutes effort on the results of eight samples by a medical 
technologist at a cost of $30 per hour. 
10. Assumes 6 minutes effort per report by the pathologist at a cost of $250 per hour. 
11. Assumes 1 minute clerical effort per report at a cost of $25 per hour. 
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6.3 ew money for HLA-B genotyping program for British 
Columbia. 
6.3.1 Start-up 
Diagnostic laboratories are heavily regulated and they cannot introduce a test into 
the market until they can demonstrate it works the same way every time.  When a 
diagnostic test is not commercially available, laboratories must not only invent their own 
in-house assay; but also challenge that assay in every conceivable way in order to identify 
the conditions under which it does and does not work.  This means that in addition to the 
obvious chemical reaction conditions (e.g. reagents, concentrations, temperature etc), it is 
necessary to establish acceptable pre-laboratory conditions including sample collection, 
storage, and shipping conditions. In addition, it is necessary to identify as much as 
possible, interfering substance that could alter the results of the test. Only after all this 
work is complete is the assay considered validated and ready for the market. 
Because of the experimental nature of the work, the time and cost associated with 
validating a molecular diagnostic test is uncertain.  However, the laboratory at Women’s 
and Children’s Hospital has been performing this type of work for over 10 years and it is 
anticipated that it will be able to validate a HLA-B assay for carbamazepine therapy in 
the minimum possible time at the minimum possible costs.  It is estimated that validating 
a new assay and creating the laboratory systems (database, forms etc) necessary to handle 
the new work will require a minimum of $3000 excluding labour. 
6.3.2 Operations 
With the current infrastructure in place, the molecular diagnostic laboratory at 
Children’s and Women’s hospital could easily integrate the anticipated demand into its 
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current operations for BC (or all of Canada).  No new personnel or equipment would be 
required.  Thus the only relevant costs would be variable costs, which range from 
approximately $3,000 to $20,000 based on the worst to the best case scenario.  These 
monies include all costs associated with blood collection shipping and laboratory 
operations. Based on projected demand (Table 4), the program will need approximately 
$10,500 in new money for operations by year 3.   
 
Figure 7: ew Operation Money required for BC HLA-B genotyping based 
on projected demand. 
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7:  HLA-B GEOTYPIG FOR THE REST OF CAADA 
7.1 Cost Analysis 
Given the investment involved in developing a validated assay and the relative 
ease and practicality of integration of the work into the BC program, it makes sense to 
extend the HLA-B genotyping service to the rest of Canada.  The objective would be to 
offer the service at a marginal profit in order to augment the British Columbian program. 
With the exception of Ontario, no other province has sufficient numbers of patients 
(Table 2) to justify development of its own program and therefore all are likely to be 
open to externally sourcing of this service.  With respect to Ontario, there is precedent for 
outsourcing genotyping service as HIV resistance testing for that province has been 
performed at St Paul’s hospital in Vancouver for over eight years.  Thus, conditions may 
be favourable for the molecular testing laboratory at Children’s and Women’s hospital to 
become the national reference laboratory for HLA-B genotyping for carbamazepine 
sensitivity.  
As phlebotomy and shipping cost would be borne by the originating province, it is 
only the laboratory expenses which are relevant to the consideration of the cost of 
providing HLA-B genotyping for the rest of Canada.  As previously mentioned, costs are 
based on batch size, and therefore there are a number of scenarios that must be 
considered.  In theory, the laboratory could be required to test as few as one non-BC 
sample per week or as many 32 for all the at - risk patients that are projected to newly 
initiate carbamazepine somewhere in the rest of Canada (Table 2).  Thus the per sample 
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cost of providing HLA-B genotype testing for the rest of the country could conceivable 
fall between approximately $44 and $103 (Figure 8). 
 
Figure 8: Changes in direct per-sample laboratory costs associated with 
HLA-B genotyping with increasing batch size. 
7.2 Pricing 
Cost analysis provides a reference point when considering pricing strategies for a 
new product or service; however, other factors also play an important role in the final 
decision.  It is also necessary to consider the market and the price that it will accept, the 
competition and how they are likely to respond, the risk and the organizations tolerance 
of risk, and finally the organizational strategy and how the new offerings fit into that 
strategy.  Each of these issues is discussed with respect to HLA-B genotyping for 
carbamazepine sensitivity.  
To eliminate risk, the discussion of pricing for the genotyping service should 
begin at around $100 per test as this is the potential cost of a single test in the worst case 
scenario (i.e. one test per week).  The ability to raise the price above this limit to generate 
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profit is then dependent upon what consumers are willing to accept.  While the price of 
genetic tests can reach thousands of dollars, the most relevant comparable is probably 
HLA-B testing for abacavir sensitivity which is almost identical to the HLA-B test 
proposed here.  In the United States, list prices for this test range from $70 to $150 (John 
Hopkins, 2008; United States Department of Veterans Affairs, 2008) which roughly 
translates to $80 to $175 in Canada.  Thus, setting the price point above $100 is not 
inconsistent with market expectations.  Indeed, relatively simple genetic tests for 
heritable disease list for approximately $250 per test in Canada (Childrens Hosptial of 
Eastern Ontario, 2007). 
In a business such as this with low volumes and high fixed costs there is a strong 
inclination to maximize margins; however, there are good reasons to exercise restraint in 
setting the price for this test.  First, the price should not be so high that it becomes 
prohibitive in the minds of physicians or health authorities in other parts of the country. 
Ambivalence about the value of the test and specimen shipping costs (ca. $40 from 
Toronto Ontario) may prove to be discouraging issues for other parts of the country and it 
may take lower pricing to compensate. Furthermore, a lower price will likely discourage 
other Canadian laboratories from developing the same service as there would be no profit 
in splitting the market.  Also, prices should not deviate too far from those in the United 
States as the border between the two countries provides a negligible barrier to having the 
analysis done there. Thus keeping the price reasonably low maximizes the chances of 
achieving and maintaining a monopoly for this service in Canada which in theory will 
increase volumes and subsequently margins and profit.  The risk in this strategy is if the 
expected volumes never materialize. 
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Maximizing price also has merit.  In the event that demand does not meet 
expectations due to market indifference or unexpected competition, the laboratory could 
maximize profit.  On the other hand, this strategy might create a self fulfilling scenario 
depending on the price elasticity of supply and demand.  If higher prices encourage 
competition in the market and/or induce physicians to reserve the test only for their 
neediest patients, the laboratory would never be able to realize the economies of scale. In 
light of these concerns, two price points will be examined: $99 and $149. 
Table 6 and Figure 9 show the potential gross profits that could be realized by the 
out-of-province genotype program under the two different pricing strategies.  Three sales 
volume scenarios are examined.  All things being equal, the higher price point yields 
more profit; however, because it has the potential to increase competition and decrease 
demand, there is the possibility that these increased profits will not be realized.  It can be 
seen from Figure 9 that the profit advantage of the $149 price point would be lost if the 
demand dropped to half that of the lower priced model.  Such a dramatic drop would 
more likely be associated with competitive entry into the market rather than a significant 
drop in subscription to the test because the price elasticity of demand among early 
adopters (i.e. those with vulnerable patients) is not expected to be great. 
Based on the examination presented here, it is recommended that the price of the 
test be set at $99 per patient. This is not only consistent with comparable tests, but it 
would also allow the laboratory to achieve reasonable profits by encouraging demand, 
discouraging competition and increasing margins by leveraging the economies of scale. 
Importantly, profit under the medium term projected demand (10 tests per week) will be 
more than enough to subsidize the BC program. While aggressive, the lower price would 
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Table 6: Annual Gross profits based of sales volume and price. 
 $99 per test $149 per test 
 Worst 
Casea 
Projected 
Caseb 
Best  
Casec 
Worst 
Casea 
Projected 
Caseb 
Best  
Casec 
Annual 
Revenues 
5,148 50,490 164,736 7,748 75,990 247,936 
COGSd 5,330 24,774 72,431 5,330 24,774 72,431 
Gross Profit -182 25,716 92,305 2,418 51,216 175,505 
a)  One test per week b) 10 tests per week c) 32 tests per week d) Cost of Goods Sold 
 
 
Figure 9: Annual gross profits by price point and sales volume 
generate enough to cover all direct costs associated with providing this service under the 
worst case scenario (one test per week).  Even under these circumstances the out-of-
province program would still be subsidizing the BC program as the weekly costs of batch 
controls will be applied to the external patient sample. 
Thus, even under the ‘next to worst’ circumstances (no external sales would be 
worse), the out-of-province genotyping program has a good potential to help pay for the 
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BC program while at the same time establishing the molecular genetics laboratory at 
Children’s and Women’s Hospital as a leader in the field of safety pharmacogenetics. If 
the lower pricing strategy is successful in cornering the Canadian market for this service, 
the laboratory will have succeeded in extending its reach and creating a place for itself in 
the consciousness of medical professionals across the country.  This should make the 
introduction of future pharmacogenetic tests easier. This position would be lost if the 
laboratory were to lose some or all this work to other laboratories and it is the opinion of 
the author that the lower price strategy provides the best potential for meeting all of the 
laboratory’s goals and objectives. 
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8:  COMMERCIALIZATIO PLA 
The public healthcare markets in Canada are similar to most other markets with 
the exception of the distance between vendors with new technologies and the ultimate 
payers.  In this country, provincial health authorities hold the purse strings and they are 
well insulated from those with new products or services to sell.  Funding decisions are 
usually based on a groundswell of support from the end users and therefore the key to 
successful commercialization of a new offering depends on convincing a critical mass of 
physicians of the value.  In practice, this generally means convincing the majority of 
opinion leaders and ideally, achieving recommendation in treatment guidelines.  As 
previously discussed, physicians need to be satisfied that the new technology provides a 
solution to a need that is as good as, or better than the alternatives and doesn’t create 
more problems than it is worth. 
The only sure way to gain acceptance for a new medical technology is to 
complete a prospective randomized clinical trial that demonstrates a significant 
improvement in outcomes when the technology is used to manage therapy versus when it 
is not.  Unfortunately in the case of HLA-B genotyping for carbamazepine sensitivity, 
this cannot be accomplished in North America because there are simply not enough 
patients of Han Chinese descent to power such a study.  At this time, professional 
acceptance of this test will have to depend on the results of the retrospective studies; 
however, there are those in the medical community who are intrinsically mistrustful of 
these types of studies because there is no assurance that the medical records (or the 
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interpretation thereof) used for these analyses are consistent or correct as the data was 
usually not collected with the study in mind. 
Because of this potential controversy, and because it is a respected part of the 
medical community, the molecular diagnostic laboratory at Women’s and Children’s 
hospital will be restricted in its promotional efforts. It must be very cautious about 
appearing to be too profit motivated (in the rest of Canada) by pushing a test that the 
medical community is undecided about.  Promotion will necessarily be limited to 
informing patients and physicians of the availability of the tests and making it as easy as 
possible to access; however, it would be in the best interest of the program if the 
laboratory were to align itself with an academic champion(s) of such testing and support 
any research efforts in which that/those individuals may be engaged. 
8.1 Launching in BC 
A potential timetable for launching the HLA-B genotyping program for 
carbamazepine sensitivity is given in Figure 10.  It is recommended that the test be 
launched in British Columbia approximately three months prior to launch in the rest of 
the country.  This will provide time to work out any operational issues and a chance to 
better understand the market for the test in an environment where there is no issue around 
payment.  It will give a better idea of who is accessing the test and from where allowing 
for refinement of the communication plan when the test is launched in the rest of Canada.  
Also, it may serve to identify visionaries and champions outside the province as word of 
the availability of the test is almost certain to diffuse to other provinces during that time. 
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Figure 10: Proposed timetable for the role out of HLA-B genotyping testing in BC 
and the rest of Canada 
It is estimated that the assay will take four months to develop assuming adequate 
commitment of resources and depending upon the availability of controls and standards.  
During the development period the laboratory can begin its marketing efforts by 
recruiting those in the neurological community who support the testing (if possible).  Pre-
announcing release of the test via channels selectively targeting neurologist (e.g. 
Neurology BC) may be enough to initiate debate and determine who is positioned on 
each side of the argument. Approximately one month prior to launch, a more general 
announcement should be made by exploiting the following channels (listed according to 
priority). 
• General mailing: Informational packages including test description, order 
forms and specimen collection instruction should be delivered to all 
appropriate physicians (neurologists, GPs and psychiatrists) in the provinces 
as well as the Directors and Heads of Hospital Medical and Pharmacy 
Departments across the province. 
• Professional Societies: Information packages should be distributed to all 
appropriate professional associations and societies in the province (BCMA, 
College of Physicians and Surgeons, Neurology BC, BC College of Family 
Physicians, College of Registered Nurses of BC, BC Pharmacy Society etc.).  
Year
Quarter Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
Develop Assay
BC Launch
ROC Launch
2008
Free
2009 2010 2011
Transition For a Fee
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If possible, the laboratory should get this information in newsletters 
distributed by these organizations.  
• Patient Advocacy Groups:  Multilingual Information packages should be 
distributed to the appropriate patient advocacy groups in the province (BC 
Epilepsy Society, Mood Disorders Association of BC, etc). 
Once the program is up and running, the following communications channels should 
be utilized to maintain awareness and advance the debate. In order of decreasing 
priority: 
• Scientific/Medical Presentations and Publications: Ideally this program 
should be launched in association with a research program (e.g. prevalence of 
the HLA-B*1502 genotype, genetic determinants of SJS/TEN within the drug 
class, physician response to test results etc.) spearheaded by a credible 
member of the academic medical/scientific community who is willing to 
champion the test.  Publication/presentation of the results of these studies will 
serve to maintain positive public exposure for the laboratory and the program.  
Leverage within the medical and scientific communities is dependent on 
research programs and without some sort of ongoing exposure in these 
channels, the laboratory will fail to establish itself leader in safety 
pharmacogenetics. 
• Continuing Medical Education (CME):  If possible, champions of the test 
should attempt to influence associated CME events and publications such that 
the regulatory recommendations for the tests continue to be presented around 
the discussion of carbamazepine. 
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• Media:  If possible, the laboratory should employ the local media to reinforce 
the message (BC CTV, Vancouver Sun, Fairchild TV).  Although this is not 
the first program of its kind in Canada, pharmacogenetics is a relatively new 
field and the local media generally repeat these stories about once a year.  
This channel is not necessarily useful to reach physicians but will assure that 
the contributions of the laboratory are reinforced in the minds of the 
government and health authorities. 
8.2 Launching in the rest of Canada 
When the test is released to the rest of Canada, there will be no public money to 
pay for the test and it can be a very long road to getting a new technology on the 
reimbursement schedules of the provincial health insurance plans.  It almost always 
begins with the recruitment of a few visionaries who champion the offerings first to the 
profession, and then the authorities.  During this process, vendors often must supply 
goods and service for free in order to support the efforts of their champions. For drugs 
and commercial diagnostic products, the process begins during clinical trials – well 
before they make it to market.  Even if approved by Health Canada, provincial authorities 
often insist on additional studies to determine how new technologies best fit into existing 
healthcare services. In order to expedite the process, the laboratory will likely have to 
provide free HLA-B genotyping for carbamazepine sensitivity for a period of 12 to 18 
months. 
The initial release of the test in the rest of Canada should be a more muted process 
than BC.  Introduction should focus on both Provincial and National professional 
societies (Canadian Medical Association, The Association of Ontario Neurologists, etc) 
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and patient advocacy groups (Epilepsy Canada, Epilepsy Ontario etc) with more direct 
efforts concentrated on centres with large Asian populations. Initial mailings should be 
targeted towards neurologist and GPs practicing in large Asian catchment areas of 
Toronto and neurologists in Montreal, Edmonton, Calgary and Ottawa. 
Extra attention should be focused on Toronto.  Prior to launch, the laboratory 
should work with public and private blood collection facilities in the city and/or the 
province to establish systems to expedite delivery of specimens to the laboratory in 
Vancouver.  This has already been done for HIV resistance testing and the laboratory 
may be able to model the approach taken there.  In addition, accelerating the delivery of 
results by setting up electronic reporting systems would likely increase satisfaction with 
the test. By concentrating on the Toronto area, the laboratory will be assuring familiarity 
with the test among practitioners serving the largest Asian community in the country. 
Awareness of the test is sure to diffuse out from there as communications channels in the 
medical community are extraordinarily efficient and ideal for viral marketing.  Word of 
the test should spread readily and early adopters outside the Toronto area will be able to 
access the laboratory and the test via colleagues, the internet or by directly contacting the 
laboratory. 
Importantly, the initial announcements should clearly indicate that the testing 
service will be provided for free for a limited time. Free testing is a fundamental part of 
the business development plan; however, the laboratory must press the issue of 
reimbursement at no later than eight months after launch.  To do this, it should provide 
four months notice of termination of the free service but be prepared to continue 
providing free access for as much of as eight months.  This will force physician that have 
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come to rely on the test to lobby their provincial or regional health authorities for 
funding; although these efforts are likely to take more than four months. 
The transition from free to for fee provision of HLA-B genotyping will require 
some finesse because every province must allocate and approve funding.  Most marketing 
efforts will be focussed on Toronto but it is assumed that practitioners in other 
jurisdictions will be seeking out and utilize the test during the free trial period; however, 
they likely to be behind in the process of securing funding.  Provincial approval of 
funding is likely to be staggered and it will be difficult to sustain a situation where one 
province is receiving the service for free while others are paying.  Once the first province 
signs on there should be a six month limit to the withdrawal of free services for the rest of 
the country. 
Finally, the program should be launched in association with a champion in the 
research community and/or as part of a research initiative if possible.  Having a credible 
advocate increases the chances that the test will gain wide scale adoption ultimately 
receive public funding in other provinces. 
8.3 Financial requirements 
The strategy for launch of HLA-B genotyping for carbamazepine therapy will 
require significant funds for business development. For example, approximately $17,000 
will be required over a period of 18 months to provide free access to the service in other 
provinces while physicians in those jurisdictions secure funding.  In addition, 
approximately $23,000 more will be needed for activities such as preparing guidelines for 
clinical application of the test and for direct mailings for physicians across the country.  
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These figures also include $10,000 over a two year period to cover travel expenses to 
various parts of the country for purposes such as educating physicians, coordinating 
shipping logistics, presenting research results or alternatively hosting associated 
researchers.  With these and the other expenses previously discussed (start-up and 
operations of the BC program), the program is not expected to see a profit until the 
second quarter of 2011.  The annual financial outlook based on the timetable presented in 
Figure 10 is provided in Table 7. 
Table 7: Four year projected financial outlook for HLA-B genotyping 
program for carbamazepine sensitivity 
Year 2009 2010 2011 2012 
     
     
Salesa   29,452 50,488 
COGS 2,275 10,728 17,541 22,896 
Gross Profit -2,275 -10,728 11,911 27,592 
     
Operations     
Assay & Systems Developmentb -5,000    
BC Programc -2,970 -4,444 -5,631 -5,852 
     
Business Development     
Preparation of guidelinesd -2,500    
Direct Mailingse -8,000    
Travelf -5,000 -5,000   
Balance -25,745 -20,172 6,152 21,740 
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otes for Table 7 
a) Based on projected demand in the rest of Canada (Table 4) and proposed 
timetable in Figure 10. 
b) ca. estimated costs of acquiring controls, standards and developing the assay 
and databases for data tracking and report generation. 
c) Based on projected demand for BC (Table 4) and proposed timetable in Figure 
10. 
d) For the preparations of guidelines for utilization of the test – based on an 
estimated 10 hours work for a neurologist(s) at $250 per hour. 
e) Estimated direct mailing costs to 5,000 general practitioners and 650 
psychiatrist in BC and 770 neurologists nationwide. 
f) Contingency funds for travel for the purposes of business development 
(presentation of program or research results, logistical arrangements etc.). 
 69 
9:  RISK AD OPPPORTUITIES 
9.1 Risk 
While the analysis presented here predicts a moderate revenue stream from an 
HLA-B genotyping program for carbamazepine therapy, it has included numerous estimates 
and assumptions based on the best available information at this time.  Variables such as 
demand or competitive responses to the introduction of this test cannot be guaranteed and can 
change due to unforeseen circumstances. Therefore all such analyses contain inherent risks 
that must be taken into account.  Such risks associated with the initiation of a provincial and 
nation-wide program of HLA-B genotyping for carbamazepine sensitivity are detailed and 
qualitatively assessed with respect to probability and impact in Table 8. 
Table 8: Risks associated with the initiation of HLA-B genotyping for 
carbamazepine sensitivity 
Risk Comments Estimated 
Probabilitya 
Estimated 
Impacta 
o Demand in BC - Investment of $14,000 for a test 
nobody wants. 
low low 
    
Underestimate of 
the Demand in BC 
- The rate and extent of utilization of 
the test could be greater than projected 
- maximum operating requirements of 
ca. $20,000 starting in the first year 
moderate low 
    
o Demand from 
ROC 
- Investment of $5,000 
- No subsidy for BC Program 
moderate low 
    
Less demand in 
ROC or 
competition 
 - Reduces or eliminates extra-
provincial work and subsidy for BC 
program 
- At least 9 laboratory is the country 
have the capabilities to offer these 
services 
- lowers laboratories profile in Canada 
moderate low 
a) Judgement based estimates. 
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9.2 Opportunities 
In addition to the risk, involvement in a safety pharmacogenetics program such as 
this presents some potential opportunities.  Table 9 list some of the opportunities.  In 
many cases the probability and/or impact of these opportunities cannot be judged with 
confidence because not enough is known about these potentials; however the ideas 
presented in this table should serve as a starting point for further research. 
Table 9: Opportunities associated with the initiation of HLA-B genotyping for 
carbamazepine sensitivity 
Opportunities Comments Estimated 
Probabilitya 
Estimated 
Impacta 
Demand from 
the United State 
- Over 4.5 million people of Asian descent 
living on the Pacific Coast of the US (US 
Census Bureau, 2006) which suggest a 
greater market than all of Canada 
- would require CLIA and CAP 
certification to serve this region 
moderate unknown 
    
Demand for 
Other Drugs 
- The same HLA-B polymorphism has been 
implicated in SJS/TEN cases associated 
with phenytoin and lamotrigine use (Man 
CBL, 2007) 
 - requires confirmation 
unknown unknown 
    
Cost reduction 
for ROC by 
switching to 
buccal swabs or 
blood spots 
- Technology is available for automated 
isolation of DNA from these types of 
specimens 
- may require a change in clinical protocols 
for neurologists. 
moderate low 
    
Future 
Collaborations 
- superior service and research presentation 
have the potential to attract collaborators 
on future genotyping testing studies 
moderate moderate 
a) Judgement based estimates 
. 
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9.3 Conclusion 
Although there are clear financial risks associated with initiating a genotyping 
program for carbamazepine sensitivity, these are relatively minor and the potential 
benefit is much greater.  In addition to making life safer for patients in British Columbia, 
the laboratory has the opportunity to help patients in the rest of the country as well while 
realizing a modest profit at the same time.  The intangible benefits of this are invaluable.  
Such a program would provide the laboratory with an opportunity to extend its reach and 
develop networks in the medical community which do not currently exist.  This would 
almost certainly lead to other commercial and research opportunities as the laboratory 
gained a reputation in these circles. 
Importantly, realizing the benefits of the program will require a certain degree of 
commitment on the part of the leaders.  Marketing considerations should be at least as 
important as the science/research; although, the two are inextricably linked.  While 
associating the service with the strong research program of the Canadian 
Pharmacogenomics Network for Drug Safety is probably the strongest marketing strategy 
of all, the laboratory must remain attentive to its message and continuously exploit all 
available channels to keep the story alive.  In addition, the laboratory should strive to 
pursue all future opportunities in pharmacogenetic services.  HLA-B testing for 
carbamazepine sensitivity is meant to be only the beginning and the laboratory must be 
vigilant in searching for the next big opportunity if it wants to establish and maintain a 
position as a major leader in safety pharmacogenetics. 
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10:  APPEDICES 
Appendix A 
 
 
Objective 
The objective was to identify patients newly administered the chemical Carbamazepine. 
This was done separately according to region, age and gender. 
Study Period 
January 1st, 2003 through December 31st, 2007 
Data Source 
The data is extracted from the Brogan Inc. Private Drug Plan Database.  
Methodology 
New to chemical patients were those who did not show a claim for Carbamazepine in the 
year prior to their first claim in the study period. 
Patients are unique according to age, gender and province. 
New to Chemical Carbamazepine Patients 
Year Province Age Gender Chemical Claimants 
2003 AB <19 F Carbamazepine 96 
2003 AB <19 M Carbamazepine 93 
2003 AB 19+ F Carbamazepine 1,448 
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Year Province Age Gender Chemical Claimants 
2003 AB 19+ M Carbamazepine 1,109 
2003 BC <19 F Carbamazepine 61 
2003 BC <19 M Carbamazepine 66 
2003 BC 19+ F Carbamazepine 1,455 
2003 BC 19+ M Carbamazepine 1,064 
2003 East <19 F Carbamazepine 47 
2003 East <19 M Carbamazepine 48 
2003 East 19+ F Carbamazepine 1,541 
2003 East 19+ M Carbamazepine 1,048 
2003 MB <19 F Carbamazepine 11 
2003 MB <19 M Carbamazepine 10 
2003 MB 19+ F Carbamazepine 241 
2003 MB 19+ M Carbamazepine 228 
2003 ON <19 F Carbamazepine 361 
2003 ON <19 M Carbamazepine 408 
2003 ON 19+ F Carbamazepine 6,783 
2003 ON 19+ M Carbamazepine 5,058 
2003 QC <19 F Carbamazepine 81 
2003 QC <19 M Carbamazepine 83 
2003 QC 19+ F Carbamazepine 1,383 
2003 QC 19+ M Carbamazepine 1,331 
2003 SK <19 F Carbamazepine 10 
2003 SK <19 M Carbamazepine 18 
2003 SK 19+ F Carbamazepine 390 
2003 SK 19+ M Carbamazepine 288 
2004 AB <19 F Carbamazepine 62 
2004 AB <19 M Carbamazepine 84 
2004 AB 19+ F Carbamazepine 1,156 
2004 AB 19+ M Carbamazepine 1,050 
2004 BC <19 F Carbamazepine 39 
2004 BC <19 M Carbamazepine 43 
2004 BC 19+ F Carbamazepine 1,113 
2004 BC 19+ M Carbamazepine 877 
2004 East <19 F Carbamazepine 50 
2004 East <19 M Carbamazepine 44 
2004 East 19+ F Carbamazepine 1,558 
2004 East 19+ M Carbamazepine 1,108 
2004 MB <19 F Carbamazepine 11 
2004 MB <19 M Carbamazepine 16 
2004 MB 19+ F Carbamazepine 209 
2004 MB 19+ M Carbamazepine 174 
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Year Province Age Gender Chemical Claimants 
2004 ON <19 F Carbamazepine 353 
2004 ON <19 M Carbamazepine 410 
2004 ON 19+ F Carbamazepine 7,233 
2004 ON 19+ M Carbamazepine 5,290 
2004 QC <19 F Carbamazepine 57 
2004 QC <19 M Carbamazepine 103 
2004 QC 19+ F Carbamazepine 1,341 
2004 QC 19+ M Carbamazepine 1,187 
2004 SK <19 F Carbamazepine 15 
2004 SK <19 M Carbamazepine 17 
2004 SK 19+ F Carbamazepine 407 
2004 SK 19+ M Carbamazepine 323 
2005 AB <19 F Carbamazepine 59 
2005 AB <19 M Carbamazepine 82 
2005 AB 19+ F Carbamazepine 1,259 
2005 AB 19+ M Carbamazepine 966 
2005 BC <19 F Carbamazepine 51 
2005 BC <19 M Carbamazepine 46 
2005 BC 19+ F Carbamazepine 1,175 
2005 BC 19+ M Carbamazepine 930 
2005 East <19 F Carbamazepine 34 
2005 East <19 M Carbamazepine 41 
2005 East 19+ F Carbamazepine 1,334 
2005 East 19+ M Carbamazepine 985 
2005 MB <19 F Carbamazepine 9 
2005 MB <19 M Carbamazepine 19 
2005 MB 19+ F Carbamazepine 261 
2005 MB 19+ M Carbamazepine 173 
2005 ON <19 F Carbamazepine 343 
2005 ON <19 M Carbamazepine 379 
2005 ON 19+ F Carbamazepine 6,663 
2005 ON 19+ M Carbamazepine 4,941 
2005 QC <19 F Carbamazepine 60 
2005 QC <19 M Carbamazepine 68 
2005 QC 19+ F Carbamazepine 1,202 
2005 QC 19+ M Carbamazepine 1,234 
2005 SK <19 F Carbamazepine 11 
2005 SK <19 M Carbamazepine 17 
2005 SK 19+ F Carbamazepine 437 
2005 SK 19+ M Carbamazepine 307 
2006 AB <19 F Carbamazepine 65 
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Year Province Age Gender Chemical Claimants 
2006 AB <19 M Carbamazepine 82 
2006 AB 19+ F Carbamazepine 1,237 
2006 AB 19+ M Carbamazepine 1,178 
2006 BC <19 F Carbamazepine 47 
2006 BC <19 M Carbamazepine 40 
2006 BC 19+ F Carbamazepine 1,193 
2006 BC 19+ M Carbamazepine 938 
2006 East <19 F Carbamazepine 49 
2006 East <19 M Carbamazepine 38 
2006 East 19+ F Carbamazepine 1,581 
2006 East 19+ M Carbamazepine 1,080 
2006 MB <19 F Carbamazepine 28 
2006 MB <19 M Carbamazepine 15 
2006 MB 19+ F Carbamazepine 246 
2006 MB 19+ M Carbamazepine 167 
2006 ON <19 F Carbamazepine 303 
2006 ON <19 M Carbamazepine 347 
2006 ON 19+ F Carbamazepine 6,021 
2006 ON 19+ M Carbamazepine 4,429 
2006 QC <19 F Carbamazepine 59 
2006 QC <19 M Carbamazepine 69 
2006 QC 19+ F Carbamazepine 1,181 
2006 QC 19+ M Carbamazepine 1,159 
2006 SK <19 F Carbamazepine 16 
2006 SK <19 M Carbamazepine 16 
2006 SK 19+ F Carbamazepine 362 
2006 SK 19+ M Carbamazepine 282 
2007 AB <19 F Carbamazepine 75 
2007 AB <19 M Carbamazepine 78 
2007 AB 19+ F Carbamazepine 1,267 
2007 AB 19+ M Carbamazepine 992 
2007 BC <19 F Carbamazepine 52 
2007 BC <19 M Carbamazepine 50 
2007 BC 19+ F Carbamazepine 1,438 
2007 BC 19+ M Carbamazepine 1,052 
2007 East <19 F Carbamazepine 27 
2007 East <19 M Carbamazepine 38 
2007 East 19+ F Carbamazepine 1,251 
2007 East 19+ M Carbamazepine 916 
2007 MB <19 F Carbamazepine 10 
2007 MB <19 M Carbamazepine 12 
 76 
Year Province Age Gender Chemical Claimants 
2007 MB 19+ F Carbamazepine 250 
2007 MB 19+ M Carbamazepine 180 
2007 ON <19 F Carbamazepine 322 
2007 ON <19 M Carbamazepine 337 
2007 ON 19+ F Carbamazepine 5,804 
2007 ON 19+ M Carbamazepine 4,321 
2007 QC <19 F Carbamazepine 82 
2007 QC <19 M Carbamazepine 83 
2007 QC 19+ F Carbamazepine 1,246 
2007 QC 19+ M Carbamazepine 1,139 
2007 SK <19 F Carbamazepine 13 
2007 SK <19 M Carbamazepine 15 
2007 SK 19+ F Carbamazepine 375 
2007 SK 19+ M Carbamazepine 261 
 
Overall rates of capture for the Brogan Inc. private drug plan data by province are shown 
below.  Data presented in this report has not been extrapolated based on the reported 
capture rates. 
Province Capture 
Rate 
British Columbia 33% 
Alberta 37% 
Saskatchewan 52% 
Manitoba 32% 
Ontario 84% 
Quebec 73% 
Nova Scotia 83% 
Newfoundland 69% 
New Brunswick 77% 
Prince Edward 
Island 
64% 
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